Update der S 3-Leitlinie Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion, AWMF-Register-Nr.: 021 / 012

C. Sarrazin; T. Berg; R. S. Ross; P. Schirmacher; H. Wedemeyer; U. Neumann; H. H. J. Schmidt; U. Spengler; S. Wirth; H. H. Kessler; M. Peck-Radosavljevic; P. Ferenci; W. Vogel; D. Moradpour; M. Heim; M. Cornberg; U. Protzer; M. P. Manns; W. E. Fleig; M. M. Dollinger; S. Zeuzem

doi:10.1055/s-0028-1110008

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000094.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Z Gastroenterol 2010; 48(2): 289-351
DOI: 10.1055/s-0028-1110008

Leitlinie

Update der S 3-Leitlinie Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion, AWMF-Register-Nr.: 021 / 012

Prophylaxis, Diagnosis and Therapy of Hepatitis C Virus (HCV) Infection: The German Guidelines on the Management of HCV InfectionC. Sarrazin¹ [*] , T. Berg² [*] , R. S. Ross³ , P. Schirmacher⁴ , H. Wedemeyer⁵ , U. Neumann⁶ , H. H. J. Schmidt⁷ , U. Spengler⁸ , S. Wirth⁹ , H. H. Kessler¹⁰ , M. Peck-Radosavljevic¹¹ , P. Ferenci¹¹ , W. Vogel¹² , D. Moradpour¹³ , M. Heim¹⁴ , M. Cornberg⁵ , U. Protzer¹⁵ , M. P. Manns⁵ , W. E. Fleig¹⁶ , M. M. Dollinger¹⁷ [*] , S. Zeuzem¹ [*]

¹Medizinische Klinik I, Johann-Wolfgang-Goethe-Universität Frankfurt am Main
²Sektion Hepatologie, Klinik und Poliklinik für Gastroenterologie & Rheumatologie, Universitätsklinikum Leipzig
³Institut für Virologie, Universitätsklinikum Essen, Universität Duisburg-Essen
⁴Pathologisches Institut, Universitätsklinikum Heidelberg
⁵Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
⁶Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Charité Campus Virchow Berlin
⁷Transplantationshepatologie, Universitätsklinikum Münster
⁸Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn
⁹Zentrum für Kinder- und Jugendmedizin, HELIOS Klinikum Wuppertal, Universität Witten/Herdecke
¹⁰Zentrum für angewandte Biomedizin, Medizinische Universität Graz
¹¹Klinik für Innere Medizin III, Medizinische Universität Wien
¹²Klinik für Innere Medizin II, Medizinische Universität Innsbruck
¹³Service de Gastroénterologie et Hépatologie, CHUV Lausanne
¹⁴Abteilung für Gastroenterologie und Hepatologie, Universitätsspital Basel
¹⁵Institut für Virologie, Technische Universität München/Helmholtz Zentrum München
¹⁶Universitätsklinikum Leipzig
¹⁷Klinik und Poliklinik für Innere Medizin I, Martin-Luther-Universität Halle-Wittenberg

Further Information

Publication History

Publication Date:
29 January 2010 (online)

Also available at

Abstract
Full Text
References

Permissions and Reprints

Koordination: C. Sarrazin, M. Dollinger, U. Protzer, M. Cornberg

Literatur

1 Hoofnagle J H. Course and outcome of hepatitis C. Hepatology. 2002; 36 S21-S29

Google Scholar
2 Seeff L B. Natural history of chronic hepatitis C. Hepatology. 2002; 36 S35-S46

Google Scholar
3 Caruntu F A, Benea L. Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment. J Gastrointestin Liver Dis. 2006; 15 249-256

Google Scholar
4 Maheshwari A, Ray S, Thuluvath P J. Acute hepatitis C. Lancet. 2008; 372 321-332

Google Scholar
5 (CDC) CfDCaP . Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998; 47 1-39

Google Scholar
6 (NIH) NIoH . NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements. 2002; 19 1-46

Google Scholar
7 Offergeld R, Faensen D, Ritter S. et al . Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000 – 2002: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill. 2005; 10 8-11

Google Scholar
8 (CDC) CfDCaP . Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001; 50 1-43

Google Scholar
9 Li Vecchi M, La Spada E, Li Vecchi V. et al . Hepatitis C virus infection in hemodialyzed patients. Int J Artif Organs. 2007; 30 100-107

Google Scholar
10 Sulowicz W, Radziszewski A, Chowaniec E. Hepatitis C virus infection in dialysis patients. Hemodial Int. 2007; 11 286-295

Google Scholar
11 Shepard C W, Finelli L, Alter M J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5 558-567

Google Scholar
12 Alter M J. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007; 13 2436-2441

Google Scholar
13 (RKI) RK-I .Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten 2006. Berlin; RKI 2007: 98-103

Google Scholar
14 Vescio M F, Longo B, Babudieri S. et al . Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health. 2008; 62 305-313

Google Scholar
15 Alter M J. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006; 44 S6-S9

Google Scholar
16 Gaeta G B, Precone D F, Cozzi-Lepri A. et al . Multiple viral infections. J Hepatol. 2006; 44 S108-S113

Google Scholar
17 Ackerman Z, Ackerman E, Paltiel O. Intrafamilial transmission of hepatitis C virus: a systematic review. J Viral Hepat. 2000; 7 93-103

Google Scholar
18 Jain S, Goharkhay N, Saade G. et al . Hepatitis C in pregnancy. Am J Perinatol. 2007; 24 251-256

Google Scholar
19 Narkewicz M R, Cabrera R, Gonzalez-Peralta R P. The „C” of viral hepatitis in children. Semin Liver Dis. 2007; 27 295-311

Google Scholar
20 Lavanchy D, McMahon B. Worldwide prevalence and prevention of hepatitis C. In: Ljang JT, Hoofnagle J (Eds), Hepatitis C. San Diego; Academic Press 2000: 185-201

Google Scholar
21 Global Burden of Hepatitis C Working Group . Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004; 44 20-29

Google Scholar
22 Williams R. Global challenges in liver disease. Hepatology. 2006; 44 521-526

Google Scholar
23 Hüppe D, Zehnter E, Mauss S. et al . Epidemiology of chronic hepatitis C in Germany – an analysis of 10,326 patients in hepatitis centres and outpatient units. Z Gastroenterol. 2008; 46 34-44

Google Scholar
24 Thierfelder W, Hellenbrand W, Meisel H. et al . Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol. 2001; 17 429-435

Google Scholar
25 Gretch D R. Diagnostic tests for hepatitis C. Hepatology. 1997; 26 43S-47S

Google Scholar
26 Courouce A M. Development of screening and confirmation tests for antibodies to hepatitis C virus. Curr Stud Hematol Blood Transfus. 1998; 62 64-75

Google Scholar
27 Kiely P, Wilson D. Results of HCV screening of volunteer blood donors with a chemiluminescent immunoassay and a second- or third-generation EIA: overlap of false-positive reactivity and its impact on donor management. Transfusion. 2000; 40 580-584

Google Scholar
28 Pawlotsky J M. Use and interpretation of virological tests for hepatitis C. Hepatology. 2002; 36 S65-S73

Google Scholar
29 Ferreira-Gonzalez A, Shiffman M L. Use of diagnostic testing for managing hepatitis C virus infection. Semin Liver Dis. 2004; 24 (Suppl 2) 9-18

Google Scholar
30 Scott J D, Gretch D R. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA. 2007; 297 724-732

Google Scholar
31 Zaaijer H L, Vrielink H, Exel-Oehlers P J. et al . Confirmation of hepatitis C infection: a comparison of five immunoblot assays. Transfusion. 1994; 34 603-607

Google Scholar
32 Bonanni van P, Icardi G C, Raffo A M. et al . Analytical and laboratory evaluation of a new fully-automated third generation enzyme immunoassay for the detection of antibodies to the hepatitis C virus. J Virol Methods. 1996; 62 113-122

Google Scholar
33 Uyttendaele S, Claeys H, Mertens W. et al . Evaluation of third-generation screening and confirmatory assays for HCV antibodies. Vox Sang. 1994; 66 122-129

Google Scholar
34 Farci P, Alter H J, Govindarajan S. et al . Lack of protective immunity against reinfection with hepatitis C virus. Science. 1992; 258 135-140

Google Scholar
35 Laperche S, Le Marrec N, Girault A. et al . Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. J Clin Microbiol. 2005; 43 3877-3883

Google Scholar
36 Lambert N. Value of HCV antigen-antibody combined HCV assay in hepatitis C diagnosis. Dev Biol (Basel). 2007; 127 113-121

Google Scholar
37 Hnatyszyn H J. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir Ther. 2005; 10 1-11

Google Scholar
38 Weck K. Molecular methods of hepatitis C genotyping. Expert Rev Mol Diagn. 2005; 5 507-520

Google Scholar
39 Simmonds P, Bukh J, Combet C. et al . Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005; 42 962-973

Google Scholar
40 Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang. 1999; 76 149-158

Google Scholar
41 Saldanha J, Heath A, Aberham C. et al . World Health Organization collaborative study to establish a replacement WHO international standard for hepatitis C virus RNA nucleic acid amplification technology assays. Vox Sang. 2005; 88 202-204

Google Scholar
42 Ross R S, Viazov S, Sarr S. et al . Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J Virol Methods. 2002; 101 159-168

Google Scholar
43 Desombere I, Van Vlierberghe H, Couvent S. et al . Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections. J Clin Microbiol. 2005; 43 2590-2597

Google Scholar
44 Sabato M F, Shiffman M L, Langley M R. et al . Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus. J Clin Microbiol. 2007; 45 2529-2536

Google Scholar
45 Bouvier-Alias M, Patel K, Dahari H. et al . Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology. 2002; 36 211-218

Google Scholar
46 Leary T P, Gutierrez R A, Muerhoff A S. et al . A chemiluminescent, magnetic particle-based immunoassay for the detection of hepatitis C virus core antigen in human serum or plasma. J Med Virol. 2006; 78 1436-1440

Google Scholar
47 Dufour D R, Lott J A, Nolte F S. et al . Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem. 2000; 46 2027-2049

Google Scholar
48 Green R M, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002; 123 1367-1384

Google Scholar
49 Anonym. American Gastroenterological Association medical position statement: evaluation of liver chemistry tests. Gastroenterology. 2002; 123 1364-1366

Google Scholar
50 Fontana R J, Lok A S. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology. 2002; 36 S57-S64

Google Scholar
51 Gebo K A, Chander G, Jenckes M W. et al . Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology. 2002; 36 S84-S92

Google Scholar
52 Stravitz R T, Heuman D M, Chand N. et al . Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med. 2008; 121 119-126

Google Scholar
53 Thompson Coon J, Rogers G, Hewson P. et al . Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess. 2007; 11 1-206

Google Scholar
54 Trevisani F, Santi V, Gramenzi A. et al . Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?. Am J Gastroenterol. 2007; 102 2448-2457, quiz 2458

Google Scholar
55 Schirmacher P, Fleig W E, Dienes H P. Biopsy diagnosis of chronic hepatitis. Z Gastroenterol. 2004; 42 175-185

Google Scholar
56 Desmet V J, Gerber M, Hoofnagle J H. et al . Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994; 19 1513-1520

Google Scholar
57 Ishak K, Baptista A, Bianchi L. et al . Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22 696-699

Google Scholar
58 Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24 289-293

Google Scholar
59 Dienstag J L. The role of liver biopsy in chronic hepatitis C. Hepatology. 2002; 36 S152-S160

Google Scholar
60 Friedrich-Rust M, Ong M F, Martens S. et al . Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008; 134 960-974

Google Scholar
61 Poynard T, Ratziu V, Charlotte F. et al . Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001; 34 730-739

Google Scholar
62 Fattovich G, Pantalena M, Zagni I. et al . Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002; 97 2886-2895

Google Scholar
63 Missiha S B, Ostrowski M, Heathcote E J. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology. 2008; 134 1699-1714

Google Scholar
64 Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005; 42 1208-1236

Google Scholar
65 El-Serag H B, Marrero J A, Rudolph L. et al . Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008; 134 1752-1763

Google Scholar
66 Greten T F, Papendorf F, Bleck J S. et al . Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer. 2005; 92 1862-1868

Google Scholar
67 Schacherer D, Schoelmerich J, Zuber-Jerger I. The diagnostic approach to hepatocellular carcinoma. Z Gastroenterol. 2007; 45 1067-1074

Google Scholar
68 Kubitschke A, Bader C, Tillmann H L. et al . Injuries from needles contaminated with hepatitis C virus: how high is the risk of seroconversion for medical personnel really?. Internist (Berl). 2007; 48 1165-1172

Google Scholar
69 Sulkowski M S, Ray S C, Thomas D L. Needlestick transmission of hepatitis C. JAMA. 2002; 287 2406-2413

Google Scholar
70 Yazdanpanah Y, De Carli G, Migueres B. et al . Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis. 2005; 41 1423-1430

Google Scholar
71 Kubitschke A, Bahr M J, Aslan N. et al . Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. Eur J Clin Invest. 2007; 37 54-64

Google Scholar
72 Mosley J W, Operskalski E A, Tobler L H. et al . Viral and host factors in early hepatitis C virus infection. Hepatology. 2005; 42 86-92

Google Scholar
73 Thimme R, Oldach D, Chang K M. et al . Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001; 194 1395-1406

Google Scholar
74 Post J J, Pan Y, Freeman A J. et al . Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis. 2004; 189 1846-1855

Google Scholar
75 Meyer M F, Lehmann M, Cornberg M. et al . Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virol J. 2007; 4 58

Google Scholar
76 Gerlach J T, Diepolder H M, Zachoval R. et al . Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003; 125 80-88

Google Scholar
77 Mosley J W, Operskalski E A, Tobler L H. et al . The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat. 2008; 15 120-128

Google Scholar
78 Cornberg M, Protzer U, Dollinger M M. et al . Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021 / 011. Z Gastroenterol. 2007; 45 525-574

Google Scholar
79 Chung H, Kudo M, Kumada T. et al . Risk of HCV transmission after needlestick injury, and the efficacy of short-duration interferon administration to prevent HCV transmission to medical personnel. J Gastroenterol. 2003; 38 877-879

Google Scholar
80 Nukaya H, Ohno T, Sakakibara K. et al . Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment. Hepatol Res. 2007; 37 179-185

Google Scholar
81 Mehta A, Rodrigues C, Ghag S. et al . Needlestick injuries in a tertiary care centre in Mumbai, India. J Hosp Infect. 2005; 60 368-373

Google Scholar
82 Oh H S, Yi S E, Choe K W. Epidemiological characteristics of occupational blood exposures of healthcare workers in a university hospital in South Korea for 10 years. J Hosp Infect. 2005; 60 269-275

Google Scholar
83 Deterding K, Wiegand J, Gruner N. et al . Medical procedures as a risk factor for HCV infection in developed countries: do we neglect a significant problem in medical care?. J Hepatol. 2008; 48 1019-1020, author reply 1020 – 1011

Google Scholar
84 Leao J C, Teo C G, Porter S R. HCV infection: aspects of epidemiology and transmission relevant to oral health care workers. Int J Oral Maxillofac Surg. 2006; 35 295-300

Google Scholar
85 Germain J M, Carbonne A, Thiers V. et al . Patient-to-patient transmission of hepatitis C virus through the use of multidose vials during general anesthesia. Infect Control Hosp Epidemiol. 2005; 26 789-792

Google Scholar
86 Forns X, Martinez-Bauer E, Feliu A. et al . Nosocomial transmission of HCV in the liver unit of a tertiary care center. Hepatology. 2005; 41 115-122

Google Scholar
87 Ledinghen de V, Trimoulet P, Mannant P R. et al . Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years). J Hepatol. 2007; 46 19-25

Google Scholar
88 Kondili L A, Genovese D, Argentini C. et al . Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center. Eur J Clin Microbiol Infect Dis. 2006; 25 527-531

Google Scholar
89 Savey A, Simon F, Izopet J. et al . A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol. 2005; 26 752-760

Google Scholar
90 Bronowicki J P, Venard V, Botte C. et al . Patient-to-patient transmission of hepatitis C virus during colonoscopy. N Engl J Med. 1997; 337 237-240

Google Scholar
91 Quer J, Esteban J I, Sanchez J M. et al . Nosocomial transmission of hepatitis C virus during contrast-enhanced computed tomography scanning. Eur J Gastroenterol Hepatol. 2008; 20 73-78

Google Scholar
92 Biostoffverordnung. Bundesgesetzblatt Teil I 1999; 50; 1999, 2059; 2003, 2304; 2004, 3758; 2004, 3758; 2006; 2407 sowie TRBA 250 Neufassung von Mai 2006. (www.nadelstichverletzung.de)

Google Scholar
93 Berufsgenossenschaftliche Grundsätze (Deutschland) für arbeitsmedizinische Vorsorgeuntersuchungen G 42 (Tätigkeiten mit Infektionsgefährdung).

Google Scholar
94 Hepatitis C Infected Health Care Workers . London; Department of Health http://www.doh.gov.uk/hepatitisc
95 Empfehlungen der Deutschen Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) zur Prävention der nosokomialen Übertragung von Hepatitis B Virus (HBV) und Hepatitis C Virus (HCV) durch im Gesundheitswesen Tätige. Lengerich; Pabst Science Publishers 2007 (Stand: Juli 2007): 139-147

Google Scholar
96 Gunson R N, Shouval D, Roggendorf M. et al . Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol. 2003; 27 213-230

Google Scholar
97 Duckworth G J, Heptonstall J, Aitken C. Transmission of hepatitis C virus from a surgeon to a patient. The Incident Control Team. Commun Dis Public Health. 1999; 2 188-192

Google Scholar
98 Esteban J I, Gomez J, Martell M. et al . Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med. 1996; 334 555-560

Google Scholar
99 Mawdsley J, Teo C G, Kyi M. et al . Anesthetist to patient transmission of hepatitis C virus associated with non exposure-prone procedures. J Med Virol. 2005; 75 399-401

Google Scholar
100 Hepatitis C virus transmission from health care worker to patient. Commun Dis Rep CDR Wkly. 1995; 5 121

Google Scholar
101 Two hepatitis C lookback exercises – national and in London. Commun Dis Rep CDR Wkly. 2000; 10 125, 128

Google Scholar
102 Hepatitis C lookback exercise. Commun Dis Rep CDR Wkly. 2000; 10 203, 206

Google Scholar
103 Hepatitis C lookback in two trusts in the south of England. Comm Dis Rep Wkly. 2001; 21 2

Google Scholar
104 Surgeon-to-patient HCV infections raise questions. Hospital Employee Health. 2002; 88-90

Google Scholar
105 Ross R SFL, Liazov S, Roggendorf M. Lack of hepatitis C virus transmission from an infected orthopedic surgeon. Jahrestagung der Gesellschaft für Virologie,. Abstractband 2003: 179

Google Scholar
106 Ross R S, Viazov S, Roggendorf M. Phylogenetic analysis indicates transmission of hepatitis C virus from an infected orthopedic surgeon to a patient. J Med Virol. 2002; 66 461-467

Google Scholar
107 Ross R S, Viazov S, Thormahlen M. et al . Risk of hepatitis C virus transmission from an infected gynecologist to patients: results of a 7-year retrospective investigation. Arch Intern Med. 2002; 162 805-810

Google Scholar
108 Stark K, Hanel M, Berg T. et al . Nosocomial transmission of hepatitis C virus from an anesthesiologist to three patients – epidemiologic and molecular evidence. Arch Virol. 2006; 151 1025-1030

Google Scholar
109 Williams I T, Perz J F, Bell B P. Viral hepatitis transmission in ambulatory health care settings. Clin Infect Dis. 2004; 38 1592-1598

Google Scholar
110 Williams I, Perz J, Bell B. Hepatitis C virus transmission from healthcare workers to patients in the USA. J Clin Virol. 2006; 36 43-44

Google Scholar
111 HIV Infected Health Care Workers .Guidance on Management and Patient Notification and contact. London; DH Publications 2005

Google Scholar
112 Alter M J. Prevention of spread of hepatitis C. Hepatology. 2002; 36 S93-S98

Google Scholar
113 Lock G, Dirscherl M, Obermeier F. et al . Hepatitis C – contamination of toothbrushes: myth or reality?. J Viral Hepat. 2006; 13 571-573

Google Scholar
114 Mastromatteo A M, Rapaccini G L, Pompili M. et al . Hepatitis C virus infection: other biological fluids than blood may be responsible for intrafamilial spread. Hepatogastroenterology. 2001; 48 193-196

Google Scholar
115 Wang J T, Wang T H, Sheu J C. et al . Hepatitis C virus RNA in saliva of patients with posttransfusion hepatitis and low efficiency of transmission among spouses. J Med Virol. 1992; 36 28-31

Google Scholar
116 Bourlet T, Levy R, Maertens A. et al . Detection and characterization of hepatitis C virus RNA in seminal plasma and spermatozoon fractions of semen from patients attempting medically assisted conception. J Clin Microbiol. 2002; 40 3252-3255

Google Scholar
117 Tang Z, Yang D, Hao L. et al . Detection and significance of HCV RNA in saliva, seminal fluid and vaginal discharge in patients with hepatitis C. J Tongji Med Univ. 1996; 16 11-13, 24

Google Scholar
118 Orlando R, Lirussi F. Hepatitis C virus infection: sexual or non-sexual transmission between spouses? A case report and review of the literature. Infection. 2007; 35 465-468

Google Scholar
119 Wiegand J, Buggisch P, Boecher W. et al . Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006; 43 250-256

Google Scholar
120 Boonyarad V, Chutaputti A, Choeichareon S. et al . Interspousal transmission of hepatitis C in Thailand. J Gastroenterol. 2003; 38 1053-1059

Google Scholar
121 Kao J H, Liu C J, Chen P J. et al . Low incidence of hepatitis C virus transmission between spouses: a prospective study. J Gastroenterol Hepatol. 2000; 15 391-395

Google Scholar
122 Qureshi H, Arif A, Ahmed W. et al . HCV exposure in spouses of the index cases. J Pak Med Assoc. 2007; 57 175-177

Google Scholar
123 Vandelli C, Renzo F, Romano L. et al . Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol. 2004; 99 855-859

Google Scholar
124 Danta M, Brown D, Bhagani S. et al . Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS. 2007; 21 983-991

Google Scholar
125 Gotz H M, Doornum van G, Niesters H G. et al . A cluster of acute hepatitis C virus infection among men who have sex with men – results from contact tracing and public health implications. AIDS. 2005; 19 969-974

Google Scholar
126 Gambotti L, Batisse D, Colin-de-Verdiere N. et al . Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001 – 2004. Euro Surveill. 2005; 10 115-117

Google Scholar
127 Low E, Vogel M, Rockstroh J. et al . Acute hepatitis C in HIV-positive individuals. AIDS Rev. 2008; 10 245-253

Google Scholar
128 Laar van de T, Pybus O, Bruisten S. et al . Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology. 2009; 136 1609-1617

Google Scholar
129 Fischer B, Kalousek K, Rehm J. et al . Hepatitis C, illicit drug use and public health: does Canada really have a viable plan?. Can J Public Health. 2006; 97 485-488

Google Scholar
130 Martin R E, Gold F, Murphy W. et al . Drug use and risk of bloodborne infections: a survey of female prisoners in British Columbia. Can J Public Health. 2005; 96 97-101

Google Scholar
131 Verachai V, Phutiprawan T, Theamboonlers A. et al . Prevalence and genotypes of hepatitis C virus infection among drug addicts and blood donors in Thailand. Southeast Asian J Trop Med Public Health. 2002; 33 849-851

Google Scholar
132 Amon J J, Garfein R S, Ahdieh-Grant L. et al . Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994 – 2004. Clin Infect Dis. 2008; 46 1852-1858

Google Scholar
133 Fischer B, Powis J, Firestone Cruz M. et al . Hepatitis C virus transmission among oral crack users: viral detection on crack paraphernalia. Eur J Gastroenterol Hepatol. 2008; 20 29-32

Google Scholar
134 Page-Shafer K, Hahn J A, Lum P J. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. AIDS. 2007; 21 1967-1969

Google Scholar
135 Backmund M, Reimer J, Meyer K. et al . Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin Infect Dis. 2005; 40 (Suppl 5) S330-S335

Google Scholar
136 Garfein R S, Golub E T, Greenberg A E. et al . A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS. 2007; 21 1923-1932

Google Scholar
137 Latka M H, Hagan H, Kapadia F. et al . A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C. Am J Public Health. 2008; 98 853-861

Google Scholar
138 Dalgard O, Bjoro K, Hellum K. et al . Treatment of chronic hepatitis C in injecting drug users: 5 years’ follow-up. Eur Addict Res. 2002; 8 45-49

Google Scholar
139 Backmund M, Meyer K, Edlin B R. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis. 2004; 39 1540-1543

Google Scholar
140 Currie S L, Ryan J C, Tracy D. et al . A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend. 2008; 93 148-154

Google Scholar
141 Aitken C K, Lewis J, Tracy S L. et al . High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology. 2008; 48 1746-1752

Google Scholar
142 Wiese M, Grungreiff K, Guthoff W. et al . Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany – a 25-year multicenter study. J Hepatol. 2005; 43 590-598

Google Scholar
143 Santantonio T, Medda E, Ferrari C. et al . Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis. 2006; 43 1154-1159

Google Scholar
144 Corey K E, Ross A S, Wurcel A. et al . Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol. 2006; 4 1278-1282

Google Scholar
145 Hofer H, Watkins-Riedel T, Janata O. et al . Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003; 37 60-64

Google Scholar
146 Wedemeyer H, Jackel E, Wiegand J. et al . Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C. Hepatology. 2004; 39 1201-1203

Google Scholar
147 Deterding K, Wiegand J, Gruner N. et al . The german hep-net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol. 2009; 47 531-540

Google Scholar
148 Jaeckel E, Cornberg M, Wedemeyer H. et al . Treatment of acute hepatitis C with interferon alpha-2b. N Engl J Med. 2001; 345 1452-1457

Google Scholar
149 Nomura H, Sou S, Tanimoto H. et al . Short-term interferon-alpha therapy for acute hepatitis C: a randomized controlled trial. Hepatology. 2004; 39 1213-1219

Google Scholar
150 Santantonio T, Fasano M, Sinisi E. et al . Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol. 2005; 42 329-333

Google Scholar
151 Delwaide J, Bourgeois N, Gerard C. et al . Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment Pharmacol Ther. 2004; 20 15-22

Google Scholar
152 De Rosa F G, Bargiacchi O, Audagnotto S. et al . Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. J Antimicrob Chemother. 2006; 57 360-363

Google Scholar
153 Deterding K, Grüner N, Wiegand J. et al . Early versus delayed treatment of acute hepatitis C: The german HEP-NET acute HCV-III study- a randomized controlled trial. J Hepatol. 2009; 50 A1047

Google Scholar
154 Broers B, Helbling B, Francois A. et al . Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol. 2005; 42 323-328

Google Scholar
155 Amin J, Law M G, Bartlett M. et al . Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet. 2006; 368 938-945

Google Scholar
156 Neal K R, Ramsay S, Thomson B J. et al . Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut. 2007; 56 1098-1104

Google Scholar
157 Marcellin P, Pequignot F, Delarocque-Astagneau E. et al . Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol. 2008; 48 200-207

Google Scholar
158 Davis G L, Albright J E, Cook S F. et al . Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003; 9 331-338

Google Scholar
159 Buti M, San Miguel R, Brosa M. et al . Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol. 2005; 42 639-645

Google Scholar
160 Sypsa V, Touloumi G, Papatheodoridis G V. et al . Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. J Viral Hepat. 2005; 12 543-550

Google Scholar
161 Sweeting M J, De Angelis D, Brant L J. et al . The burden of hepatitis C in England. J Viral Hepat. 2007; 14 570-576

Google Scholar
162 Perz J F, Armstrong G L, Farrington L A. et al . The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45 529-538

Google Scholar
163 El-Serag H B, Davila J A, Petersen N J. et al . The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003; 139 817-823

Google Scholar
164 Tanaka Y, Kurbanov F, Mano S. et al . Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology. 2006; 130 703

Google Scholar
165 Seeff L B. Natural history of hepatitis C. Hepatology. 1997; 26 21S-28S

Google Scholar
166 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349 825-832

Google Scholar
167 Di Bisceglie A M. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997; 26 34S-38S

Google Scholar
168 Sangiovanni A, Prati G M, Fasani P. et al . The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology. 2006; 43 1303-1310

Google Scholar
169 Freeman A J, Dore G J, Law M G. et al . Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001; 34 809-816

Google Scholar
170 Pessione F, Degos F, Marcellin P. et al . Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology. 1998; 27 1717-1722

Google Scholar
171 Ghany M G, Kleiner D E, Alter H. et al . Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003; 124 97-104

Google Scholar
172 Ryder S D, Irving W L, Jones D A. et al . Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004; 53 451-455

Google Scholar
173 Hui C K, Belaye T, Montegrande K. et al . A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol. 2003; 38 511-517

Google Scholar
174 Adinolfi L E, Gambardella M, Andreana A. et al . Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001; 33 1358-1364

Google Scholar
175 Thein H H, Yi Q, Dore G J. et al . Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008; 48 418-431

Google Scholar
176 Alberti A, Benvegnu L. Management of hepatitis C. J Hepatol. 2003; 38 (Suppl 1) S104-S118

Google Scholar
177 Wilson L E, Torbenson M, Astemborski J. et al . Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology. 2006; 43 788-795

Google Scholar
178 Zarski J P, Mc Hutchison J, Bronowicki J P. et al . Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol. 2003; 38 307-314

Google Scholar
179 Zeuzem S, Diago M, Gane E. et al . Peginterferon alpha-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. 2004; 127 1724-1732

Google Scholar
180 Foster G R, Goldin R D, Thomas H C. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998; 27 209-212

Google Scholar
181 Cordoba J, Flavia M, Jacas C. et al . Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol. 2003; 39 231-238

Google Scholar
182 Forton D M, Taylor-Robinson S D, Thomas H C. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat. 2003; 10 81-86

Google Scholar
183 Carta M G, Hardoy M C, Garofalo A. et al . Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. Clin Pract Epidemol Ment Health. 2007; 3 22

Google Scholar
184 Perry W, Hilsabeck R C, Hassanein T I. Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci. 2008; 53 307-321

Google Scholar
185 Acharya J N, Pacheco V H. Neurologic complications of hepatitis C. Neurologist. 2008; 14 151-156

Google Scholar
186 Weissenborn K, Krause J, Bokemeyer M. et al . Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004; 41 845-851

Google Scholar
187 Weissenborn K, Ennen J C, Bokemeyer M. et al . Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut. 2006; 55 1624-1630

Google Scholar
188 Cacoub P, Poynard T, Ghillani P. et al . Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999; 42 2204-2212

Google Scholar
189 Ferri C, Antonelli A, Mascia M T. et al . HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis. 2007; 39 (Suppl 1) S13-S21

Google Scholar
190 Zignego A L, Ferri C, Pileri S A. et al . Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis. 2007; 39 2-17

Google Scholar
191 Hermine O, Lefrere F, Bronowicki J P. et al . Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002; 347 89-94

Google Scholar
192 Mele A, Pulsoni A, Bianco E. et al . Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood. 2003; 102 996-999

Google Scholar
193 Duberg A S, Nordstrom M, Torner A. et al . Non-Hodgkin’s lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology. 2005; 41 652-659

Google Scholar
194 Morton L M, Engels E A, Holford T R. et al . Hepatitis C virus and risk of non-Hodgkin lymphoma: a population-based case-control study among Connecticut women. Cancer Epidemiol Biomarkers Prev. 2004; 13 425-430

Google Scholar
195 Zignego A L, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol. 2007; 13 2467-2478

Google Scholar
196 Giordano T P, Henderson L, Landgren O. et al . Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007; 297 2010-2017

Google Scholar
197 Deuffic-Burban S, Deltenre P, Louvet A. et al . Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. J Hepatol. 2008; 49 175-183

Google Scholar
198 Foster G R, Fried M W, Hadziyannis S J. et al . Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alpha-2a (40KD) and ribavirin. Scand J Gastroenterol. 2007; 42 247-255

Google Scholar
199 Siebert U, Sroczynski G, Rossol S. et al . Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003; 52 425-432

Google Scholar
200 Wong J B, Davis G L, McHutchison J G. et al . Economic and clinical effects of evaluating rapid viral response to peginterferon alpha-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol. 2003; 98 2354-2362

Google Scholar
201 Shepherd J, Jones J, Hartwell D. et al . Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess. 2007; 11 1-205, iii

Google Scholar
202 McHutchison J G, Dusheiko G, Shiffman M L. et al . Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007; 357 2227-2236

Google Scholar
203 Iacobellis A, Siciliano M, Perri F. et al . Peginterferon alpha-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol. 2007; 46 206-212

Google Scholar
204 Vallisa D, Bernuzzi P, Arcaini L. et al . Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol. 2005; 23 468-473

Google Scholar
205 Sterling R K, Sanyal A J, Luketic V A. et al . Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol. 1999; 94 3576-3582

Google Scholar
206 Glicklich D, Thung S N, Kapoian T. et al . Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant recipients. Am J Gastroenterol. 1999; 94 159-163

Google Scholar
207 Martin P, Carter D, Fabrizi F. et al . Histopathological features of hepatitis C in renal transplant candidates (see comment). Transplantation. 2000; 69 1479-1484

Google Scholar
208 Cotler S J, Diaz G, Gundlapalli S. et al . Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol. 2002; 35 191-195

Google Scholar
209 Hu K Q, Lee S M, Hu S X. et al . Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. Am J Gastroenterol. 2005; 100 2010-2018

Google Scholar
210 Fabrizi F, Martin P, Dixit V. et al . Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004; 20 1271-1277

Google Scholar
211 Di Napoli A, Di Lallo D, Pezzotti P. et al . Effects of parental smoking and level of education on initiation and duration of breastfeeding. Acta Paediatr. 2006; 95 678-685

Google Scholar
212 Pereira B J, Natov S N, Bouthot B A. et al . Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1998; 53 1374-1381

Google Scholar
213 Baid-Agrawal S, Pascual M, Moradpour D. et al . Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol. 2008; 18 97-115

Google Scholar
214 Fabrizi F, Martin P, Dixit V. et al . Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005; 5 1452-1461

Google Scholar
215 Heller J, Musiolik J, Homrighausen A. et al . Occurrence and significance of autoantibodies in the course of interferon therapy of chronic hepatitis C. Dtsch Med Wochenschr. 1996; 121 1179-1183

Google Scholar
216 Empfehlungen zur HCV-Therapie bei i. v. Drogengebrauchern 2003. Suchtmed. 2003; 5 245-247

Google Scholar
217 Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?. Addiction. 2004; 99 1167-1175

Google Scholar
218 Mauss S, Berger F, Goelz J. et al . A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology. 2004; 40 120-124

Google Scholar
219 Backmund M, Meyer K, Von Zielonka M. et al . Treatment of hepatitis C infection in injection drug users. Hepatology. 2001; 34 188-193

Google Scholar
220 Robaeys G, Mathei C, Buntinx F. et al . Management of hepatitis C virus infections in intravenous drug users. Acta Gastroenterol Belg. 2002; 65 99-100

Google Scholar
221 Sylvestre D L. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend. 2002; 67 117-123

Google Scholar
222 Pariante C M, Orru M G, Baita A. et al . Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet. 1999; 354 131-132

Google Scholar
223 Pariante C M, Landau S, Carpiniello B. Interferon alpha-induced adverse effects in patients with a psychiatric diagnosis. N Engl J Med. 2002; 347 148-149

Google Scholar
224 Schaefer M, Schmidt F, Folwaczny C. et al . Adherence and mental side effects during hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups. Hepatology. 2003; 37 443-451

Google Scholar
225 Schaefer M, Hinzpeter A, Mohmand A. et al . Hepatitis C treatment in „difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007; 46 991-998

Google Scholar
226 Raison C L, Borisov A S, Broadwell S D. et al . Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005; 66 41-48

Google Scholar
227 Raison C L, Demetrashvili M, Capuron L. et al . Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005; 19 105-123

Google Scholar
228 Kraus M R, Schafer A, Al-Taie O. et al . Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat. 2005; 12 96-100

Google Scholar
229 Raison C L, Woolwine B J, Demetrashvili M F. et al . Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007; 25 1163-1174

Google Scholar
230 Schaefer M, Schwaiger M, Garkisch A S. et al . Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol. 2005; 42 793-798

Google Scholar
231 Ferenci P, Formann E, Laferl H. et al . Randomized, double-blind, placebo-controlled study of peginterferon alpha-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol. 2006; 44 275-282

Google Scholar
232 Maynard M, Pradat P, Bailly F. et al . Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). J Hepatol. 2006; 44 484-490

Google Scholar
233 Deltenre P, Henrion J, Canva V. et al . Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol. 2004; 41 462-473

Google Scholar
234 Wagner von M, Hofmann W P, Teuber G. et al . Placebo-controlled trial of 400 mg amantadine combined with peginterferon alpha-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. Hepatology. 2008; 48 1404-1411

Google Scholar
235 Mayer K E, Myers R P, Lee S S. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat. 2005; 12 559-567

Google Scholar
236 Seeff L B, Lindsay K L, Bacon B R. et al . Complementary and alternative medicine in chronic liver disease. Hepatology. 2001; 34 595-603

Google Scholar
237 Veldt B J, Hansen B E, Ikeda K. et al . Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol. 2006; 41 1087-1094

Google Scholar
238 Orlent H, Hansen B E, Willems M. et al . Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol. 2006; 45 539-546

Google Scholar
239 Huber R, Ludtke R, Klassen M. et al . Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study. Eur J Med Res. 2001; 6 399-405

Google Scholar
240 Tusenius K J, Spoek A M, Hattum van J. Exploratory study on the effects of treatment with two mistletoe preparations on chronic hepatitis C. Arzneimittelforschung. 2005; 55 749-753

Google Scholar
241 Saeian K, Bajaj J S, Franco J. et al . High-dose vitamin E supplementation does not diminish ribavirin-associated haemolysis in hepatitis C treatment with combination standard alpha-interferon and ribavirin. Aliment Pharmacol Ther. 2004; 20 1189-1193

Google Scholar
242 Kawaguchi Y, Mizuta T, Takahashi K. et al . High-dose vitamins E and C supplementation prevents ribavirin-induced hemolytic anemia in patients with chronic hepatitis C. Hepatol Res. 2007; 37 317-324

Google Scholar
243 Sarrazin C, Gartner B C, Sizmann D. et al . Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol. 2006; 44 729-737

Google Scholar
244 Michelin B D, Muller Z, Stelzl E. et al . Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA. J Clin Virol. 2007; 38 96-100

Google Scholar
245 Chevaliez S, Bouvier-Alias M, Brillet R. et al . Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology. 2007; 46 22-31

Google Scholar
246 Vermehren J, Kau A, Gartner B C. et al . Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol. 2008; 46 3880-3891

Google Scholar
247 Sarrazin C, Shiffman M L, Hadziyannis S J. et al . Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavarin response-guided therapy. J Hepatol. 2010; in press

Google Scholar
248 Poynard T, McHutchison J, Davis G L. et al . Impact of interferon alpha-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology. 2000; 32 1131-1137

Google Scholar
249 Poynard T, McHutchison J, Manns M. et al . Impact of pegylated interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002; 122 1303-1313

Google Scholar
250 Everson G T, Balart L, Lee S S. et al . Histological benefits of virological response to peginterferon alpha-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther. 2008; 27 542-551

Google Scholar
251 Joshi S, Kuczynski M, Heathcote E J. Symptomatic and virological response to antiviral therapy in hepatitis C associated with extrahepatic complications of cryoglobulimia. Dig Dis Sci. 2007; 52 2410-2417

Google Scholar
252 Ramos-Casals M, Trejo O, Garcia-Carrasco M. et al . Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. Rheumatology (Oxford). 2003; 42 818-828

Google Scholar
253 Tanaka H, Tsukuma H, Kasahara A. et al . Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer. 2000; 87 741-749

Google Scholar
254 Heathcote E J. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology. 2004; 127 S294-S302

Google Scholar
255 Yu M L, Lin S M, Chuang W L. et al . A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther. 2006; 11 985-994

Google Scholar
256 Braks R E, Ganne-Carrie N, Fontaine H. et al . Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol. 2007; 13 5648-5653

Google Scholar
257 Veldt B J, Heathcote E J, Wedemeyer H. et al . Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007; 147 677-684

Google Scholar
258 Niederau C, Bemba G, Kautz A. Socioeconomic characteristics, quality of life, and state of knowledge of patients with hepatitis C viral infection in Germany – socioeconomic aspects in hepatitis C. Z Gastroenterol. 2006; 44 305-317

Google Scholar
259 Rodger A J, Jolley D, Thompson S C. et al . The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999; 30 1299-1301

Google Scholar
260 McHutchison J G, Ware J E, Bayliss M S. et al . The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol. 2001; 34 140-147

Google Scholar
261 Younossi Jr Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology. 2007; 45 806-816

Google Scholar
262 Bernstein D, Kleinman L, Barker C M. et al . Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002; 35 704-708

Google Scholar
263 McHutchison J G, Gordon S C, Schiff E R. et al . Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339 1485-1492

Google Scholar
264 Brillanti S, Garson J, Foli M. et al . A pilot study of combination therapy with ribavirin plus interferon alpha for interferon alpha-resistant chronic hepatitis C. Gastroenterology. 1994; 107 812-817

Google Scholar
265 Di Bisceglie A M, Shindo M, Fong T L. et al . A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology. 1992; 16 649-654

Google Scholar
266 Reichard O, Andersson J, Schvarcz R. et al . Ribavirin treatment for chronic hepatitis C. Lancet. 1991; 337 1058-1061

Google Scholar
267 Zeuzem S, Heathcote J E, Martin N. et al . Peginterferon alpha-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Expert Opin Investig Drugs. 2001; 10 2201-2213

Google Scholar
268 Wang Y S, Youngster S, Grace M. et al . Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev. 2002; 54 547-570

Google Scholar
269 Manns M P, McHutchison J G, Gordon S C. et al . Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358 958-965

Google Scholar
270 Fried M W, Shiffman M L, Reddy K R. et al . Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347 975-982

Google Scholar
271 Manns M, Zeuzem S, Sood A. et al . Reduced dose and duration of peginterferon alpha-2b and weight-based ribvairin in European and Asian genotype 2 and 3 chronic hepatitis C patients (REDD 2 / 3 trial). J Hepatol. 2009; 50 A144

Google Scholar
272 Fried M, Jensen D, Rodriguez-Torres M. et al . Improved sustained virological response (SVR) rates with higher, fixed doses of peginterferon alpha-2a (40KD) plus ribavirin in patients with „difficult-to-cure” characteristics. Hepatology. 2006; 44 314A

Google Scholar
273 Sulkowski M, Lawitz E, Shiffman M. et al . Final results of the IDEAL (individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIb study. J Hepatol. 2008; 48 370A-371A

Google Scholar
274 Meyer-Wyss B, Rich P, Egger H. et al . Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naive patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat. 2006; 13 457-465

Google Scholar
275 Hadziyannis S J, Sette Jr H, Morgan T R. et al . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140 346-355

Google Scholar
276 Jacobson I M, Brown R S, Freilich Jr B. et al . Peginterferon alpha-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007; 46 971-981

Google Scholar
277 Shiffman M, Pappas S, Greenbloom S. et al . Effect of drug exposure on sustained virological response (SVR) in patients with chronic hepatitis C virus genotype 2 or 3 treated with Peginterferon alpha-2a (40kd) plus ribavirin for 16 or 24 weeks. Hepatology. 2006; 44 317A-318A

Google Scholar
278 Ferenci P, Brunner H, Laferl H. et al . A randomized, prospective trial of ribavirin 400mg/day versus 800mg/day in combination with peginterferon alpha-2a in hepatitis C virus genotypes 2 and 3. Hepatology. 2008; 47 1816-1823

Google Scholar
279 Reddy K R, Shiffman M L, Morgan T R. et al . Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alpha-2a/ribavirin treatment. Clin Gastroenterol Hepatol. 2007; 5 124-129

Google Scholar
280 McHutchison J G, Manns M, Patel K. et al . Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002; 123 1061-1069

Google Scholar
281 Snoeck E, Wade J R, Duff F. et al . Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alpha-2a (40KD) plus ribavirin. Br J Clin Pharmacol. 2006; 62 699-709

Google Scholar
282 Davis G L, Wong J B, McHutchison J G. et al . Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003; 38 645-652

Google Scholar
283 Ferenci P, Fried M W, Shiffman M L. et al . Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alpha-2a (40 KD)/ribavirin. J Hepatol. 2005; 43 425-433

Google Scholar
284 Berg T, Wagner von M, Nasser S. et al . Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alpha-2a plus ribavirin. Gastroenterology. 2006; 130 1086-1097

Google Scholar
285 Sanchez-Tapias J M, Diago M, Escartin P. et al . Peginterferon-alpha2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006; 131 451-460

Google Scholar
286 Berg T, Sarrazin C, Herrmann E. et al . Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology. 2003; 37 600-609

Google Scholar
287 Afdhal N, Levine R, Brown R. et al . Colchicine versus PEG-Interferon alpha 2b long term therapy: results of the 4 year copilot trial. J Hepatol. 2008; 48 4A

Google Scholar
288 Di Bisceglie A M, Shiffman M L, Everson G T. et al . Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2007; 46 290A

Google Scholar
289 Bruix J, Poynard T, Colombo M. et al . Pegintron maintenance therapy in cirrhotic (Metavir F 4) HCV patients, who failed to respond to interferon/ribavirin (IR) therapy: final results of the EPIC3 cirrhosis maintenance trial. J Hepatol. 2009; 50 A49

Google Scholar
290 Zeuzem S, Buti M, Ferenci P. et al . Efficacy of 24 weeks treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006; 44 97-103

Google Scholar
291 Jensen D M, Morgan T R, Marcellin P. et al . Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006; 43 954-960

Google Scholar
292 Ferenci P, Laferl H, Scherzer T M. et al . Peginterferon alpha-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008; 135 451-458

Google Scholar
293 Nasta P, Gatti F, Puoti M. et al . Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alpha-2a. AIDS. 2008; 22 857-861

Google Scholar
294 Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008; 49 634-651

Google Scholar
295 Pearlman B L, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology. 2007; 46 1688-1694

Google Scholar
296 Mangia A, Minerva N, Bacca D. et al . Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology. 2008; 47 43-50

Google Scholar
297 Ferenci P, Laferl H, Scherzer T M. et al . Customizing treatment with peginterferon alpha-2a (40KD) plus ribavirin in patients with HCV genotype 1 or 4 infection: interim results of a prospective randomized trial. Hepatology. 2006; 44 336A

Google Scholar
298 Buti M, Lurie Y, Zakharova N. et al . Extended treatment duration in chronic hepatitis C genotype 1-infected slow responders: final results of the SUCCESS study. J Hepatol. 2009; 50 A141

Google Scholar
299 Kamal S M, El Tawil A A, Nakano T. et al . Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut. 2005; 54 858-866

Google Scholar
300 Hasan F, Asker H, Al-Khaldi J. et al . Peginterferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol. 2004; 99 1733-1737

Google Scholar
301 Khuroo M S, Dahab S T. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2004; 20 931-938

Google Scholar
302 Kamal S M, El Kamary S S, Shardell M D. et al . Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology. 2007; 46 1732-1740

Google Scholar
303 Zeuzem S, Hultcrantz R, Bourliere M. et al . Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004; 40 993-999

Google Scholar
304 Shiffman M L, Suter F, Bacon B R. et al . Peginterferon alpha-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007; 357 124-134

Google Scholar
305 Dalgard O, Bjoro K, Hellum K B. et al . Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology. 2004; 40 1260-1265

Google Scholar
306 Wagner von M, Huber M, Berg T. et al . Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005; 129 522-527

Google Scholar
307 Mangia A, Santoro R, Minerva N. et al . Peginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005; 352 2609-2617

Google Scholar
308 Yu M L, Dai C Y, Huang J F. et al . A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007; 56 553-559

Google Scholar
309 Dalgard O, Bjoro K, Ring-Larsen H. et al . Pegylated interferon alpha and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. 2008; 47 35-42

Google Scholar
310 Andriulli A, Dalgard O, Bjoro K. et al . Short-term treatment duration for HCV-2 and HCV-3 infected patients. Dig Liver Dis. 2006; 38 741-748

Google Scholar
311 Mangia A, Ricci G L, Persico M. et al . A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine v. interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepat. 2005; 12 292-299

Google Scholar
312 Davis G L, Esteban-Mur R, Rustgi V. et al . Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339 1493-1499

Google Scholar
313 Sagir A, Heintges T, Akyazi Z. et al . Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection. Liver Int. 2007; 27 954-959

Google Scholar
314 Hass H G, Kreysel C, Fischinger J. et al . High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy. World J Gastroenterol. 2005; 11 5342-5346

Google Scholar
315 August-Jorg B S, Borovicka J, Dufour J F. et al . Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C. Swiss Med Wkly. 2003; 133 455-460

Google Scholar
316 Di Marco V, Almasio P, Vaccaro A. et al . Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. J Hepatol. 2000; 33 456-462

Google Scholar
317 Boucher E J, Jacquelinet S, Canva V. et al . High rate of long-term virological response after a 1-year course of interferon± ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial. Liver Int. 2003; 23 255-261

Google Scholar
318 Poynard T, Colombo M, Bruix J. et al . Peginterferon alpha-2b and ribavirin: effective in patients with hepatitis C who failed interferon alpha/ribavirin therapy. Gastroenterology. 2009; 136 1618-1628

Google Scholar
319 Basso M, Torre F, Grasso A. et al . Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. Dig Liver Dis. 2007; 39 47-51

Google Scholar
320 Jacobson I M, Gonzalez S A, Ahmed F. et al . A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol. 2005; 100 2453-2462

Google Scholar
321 Shiffman M L, Di Bisceglie A M, Lindsay K L. et al . Peginterferon alpha-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004; 126 1015-1023, discussion 1947

Google Scholar
322 Steindl-Munda P, Ferenci P, Brunner H. et al . Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy. Liver Int. 2003; 23 269-275

Google Scholar
323 Shiffman M L, Ghany M G, Morgan T R. et al . Impact of reducing peginterferon alpha-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007; 132 103-112

Google Scholar
324 Lindsay K L, Morishima C, Wright E C. et al . Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol. 2008; 6 234-241

Google Scholar
325 Jensen D M, Marcellin P, Freilich B. et al . Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009; 150 528-540

Google Scholar
326 Moucari R, Ripault M P, Oules V. et al . High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol. 2007; 46 596-604

Google Scholar
327 Diago M, Crespo J, Olveira A. et al . Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. Aliment Pharmacol Ther. 2007; 26 1131-1138

Google Scholar
328 Marcellin P, Freilich B, Andreone P. et al . Type of response to prior pegylated interferon alpha-2b (12KD)/ribavirin predicts subsequent response to retreatment with peginterferon alpha-2a (40KD)/ribavirin. J Hepatol. 2008; 48 301A

Google Scholar
329 Witthoft T, Moller B, Wiedmann K H. et al . Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial. J Viral Hepat. 2007; 14 788-796

Google Scholar
330 Hofmann W P, Bock H, Weber C. et al . [Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists]. Z Gastroenterol. 2006; 44 25-31

Google Scholar
331 Wasem J, Sroczynski G, Aidelsburger P. et al . Health economics of chronic infectious diseases: the example of hepatitis C. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006; 49 57-63

Google Scholar
332 Manns M P. Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterol Clin North Am. 2004; 33 S11-S24

Google Scholar
333 Nakamura J, Kobayashi K, Toyabe S. et al . The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C. Eur J Gastroenterol Hepatol. 2007; 19 733-739

Google Scholar
334 Nakamura J, Toyabe S I, Aoyagi Y. et al . Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders. J Viral Hepat. 2008; 15 293-299

Google Scholar
335 Dammacco F, Sansonno D, Han J H. et al . Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood. 1994; 84 3336-3343

Google Scholar
336 Ferri C, Marzo E, Longombardo G. et al . Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood. 1993; 81 1132-1136

Google Scholar
337 Mazzaro C, Zorat F, Caizzi M. et al . Treatment with peg-interferon alpha-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol. 2005; 42 632-638

Google Scholar
338 Saadoun D, Delluc A, Piette J C. et al . Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol. 2008; 20 23-28

Google Scholar
339 Saadoun D, Resche-Rigon M, Sene D. et al . Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis. 2008; 67 1431-1436

Google Scholar
340 Mazzaro C, Franzin F, Tulissi P. et al . Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer. 1996; 77 2604-2613

Google Scholar
341 Zuckerman E, Zuckerman T, Sahar D. et al . The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood. 2001; 97 1555-1559

Google Scholar
342 Johnson R J, Gretch D R, Yamabe H. et al . Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 1993; 328 465-470

Google Scholar
343 Orlent H, Mathot R A, Van Bommel E F. et al . Peginterferon and dose-titrated ribavirin for hepatitis C-associated nephrotic membranoproliferative glomerulonephritis type 1. Dig Dis Sci. 2005; 50 1804-1806

Google Scholar
344 Cua I H, Kwan V, Henriquez M. et al . Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis. Gut. 2006; 55 1521-1522

Google Scholar
345 Protzer U, Ochsendorf F R, Leopolder-Ochsendorf A. et al . Exacerbation of lichen planus during interferon alpha-2a therapy for chronic active hepatitis C. Gastroenterology. 1993; 104 903-905

Google Scholar
346 Heintges T, Frieling T, Goerz G. et al . Exacerbation of lichen planus but not of acute intermittent hepatic porphyria during interferon therapy in a patient with chronic hepatitis C. J Hepatol. 1994; 21 1152-1153

Google Scholar
347 Nagao Y, Kawaguchi T, Tanaka K. et al . Extrahepatic manifestations and insulin resistance in an HCV hyperendemic area. Int J Mol Med. 2005; 16 291-296

Google Scholar
348 Varela P, Areias J, Mota F. et al . Oral lichen planus induced by interferon-alpha-N1 in a patient with hepatitis C. Int J Dermatol. 2000; 39 239-240

Google Scholar
349 Papini M, Bruni P L, Bettacchi A. et al . Sudden onset of oral ulcerative lichen in a patient with chronic hepatitis C on treatment with alpha-interferon. Int J Dermatol. 1994; 33 221-222

Google Scholar
350 Nagao Y, Sata M, Ide T. et al . Development and exacerbation of oral lichen planus during and after interferon therapy for hepatitis C. Eur J Clin Invest. 1996; 26 1171-1174

Google Scholar
351 Sheikh M Y, Wright R A, Burruss J B. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C. Dig Dis Sci. 1998; 43 529-533

Google Scholar
352 Jessner W, Der-Petrossian M, Christiansen L. et al . Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C. Hepatology. 2002; 36 1301-1302

Google Scholar
353 Thevenot T, Bachmeyer C, Hammi R. et al . Occurrence of porphyria cutanea tarda during peginterferon/ribavirin therapy for chronic viral hepatitis C. J Hepatol. 2005; 42 607-608

Google Scholar
354 Fernandez I, Castellano G, Salamanca R E. et al . Porphyria cutanea tarda as a predictor of poor response to interferon alpha therapy in chronic hepatitis C. Scand J Gastroenterol. 2003; 38 314-319

Google Scholar
355 Gordon C E, Uhlig de K, Lau J. et al . Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis. 2008; 51 263-277

Google Scholar
356 Fabrizi F, Dulai G, Dixit V. et al . Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther. 2003; 18 1071-1081

Google Scholar
357 Amarapurkar D N, Patel N D, Kirpalani A L. Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients undergoing haemodialysis. Trop Gastroenterol. 2007; 28 16-18

Google Scholar
358 Casanovas-Taltavull T, Baliellas C, Llobet M. et al . Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis. Transplant Proc. 2007; 39 2125-2127

Google Scholar
359 Covic A, Maftei I D, Mardare N G. et al . Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol. 2006; 19 794-801

Google Scholar
360 Kokoglu O F, Ucmak H, Hosoglu S. et al . Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006; 21 575-580

Google Scholar
361 Sporea I, Popescu A, Sirli R. et al . Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol. 2006; 12 4191-4194

Google Scholar
362 Liu C H, Liang C C, Lin J W. et al . Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut. 2008; 57 525-530

Google Scholar
363 Peck-Radosavljevic M, Boletis J, Besisik F. et al . Low-dose peginterferon alpha-2a (40KD) to treat hepatitis C-infected, end-stage renal disease patients undergoing haemodialysis: final study results. J Hepatol. 2008; 48 374A

Google Scholar
364 Russo M W, Ghalib R, Sigal S. et al . Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2006; 21 437-443

Google Scholar
365 Bruchfeld A, Lindahl K, Reichard O. et al . Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat. 2006; 13 316-321

Google Scholar
366 Rendina M, Schena A, Castellaneta N M. et al . The treatment of chronic hepatitis C with peginterferon alpha-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol. 2007; 46 768-774

Google Scholar
367 Leusen van R, Adang R P, Vries R A. et al . Pegylated interferon alpha-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2008; 23 721-725

Google Scholar
368 Polifka J E, Friedman J M. Developmental toxicity of ribavirin/IFalpha combination therapy: is the label more dangerous than the drugs?. Birth Defects Res A Clin Mol Teratol. 2003; 67 8-12

Google Scholar
369 Mubarak A A, Kakil I R, Awidi de A. et al . Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-alpha in 1^st trimester: report of 3 cases and review of the literature. Am J Hematol. 2002; 69 115-118

Google Scholar
370 Kochhar D M, Penner J D, Knudsen T B. Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol. 1980; 52 99-112

Google Scholar
371 Ferm V H, Willhite C, Kilham L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratology. 1978; 17 93-101

Google Scholar
372 Johnson E M. Developmental toxicity and safety evaluations of ribavirin. Pediatr Infect Dis J. 1990; 9 S85-S87

Google Scholar
373 Maddrey W C. Safety of combination interferon alpha-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis. 1999; 19 (Suppl 1) 67-75

Google Scholar
374 Hegenbarth K, Maurer U, Kroisel P M. et al . No evidence for mutagenic effects of ribavirin: report of two normal pregnancies. Am J Gastroenterol. 2001; 96 2286-2287

Google Scholar
375 Atmar R L, Englund J A, Hammill H. Complications of measles during pregnancy. Clin Infect Dis. 1992; 14 217-226

Google Scholar
376 Bianca S, Ettore G. Male periconceptional ribavir-ininterferon alpha-2b exposure with no adverse fetal effects. Birth Defects Res A Clin Mol Teratol. 2003; 67 77-78

Google Scholar
377 Taguchi N, Ito S. Paternal use of ribavirin-interferon alpha 2B combination therapy before conception. Can Fam Physician. 2005; 51 1623-1625

Google Scholar
378 De Santis M, Carducci B, Cavaliere A F. et al . Paternal exposure to ribavirin: pregnancy and neonatal outcome. Antivir Ther. 2003; 8 73-75

Google Scholar
379 Neri S, Bruno C M, Abate G. et al . Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther. 2002; 24 1627-1635

Google Scholar
380 Reimer J, Schulte B, Castells X. et al . Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries. Clin Infect Dis. 2005; 40 (Suppl 5) S373-378

Google Scholar
381 Backmund M, Goelz J, Kaiser S. et al . Empfehlungen zur HCV-Therapie bei i. v. Drogengebrauchern. Suchtmed. 2003; 5 245-247

Google Scholar
382 Ono K, Sata M, Murashima S. et al . Biological responses to administered interferon in alcoholics. Alcohol Clin Exp Res. 1996; 20 1560-1563

Google Scholar
383 Ohnishi K, Matsuo S, Matsutani K. et al . Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol. 1996; 91 1374-1379

Google Scholar
384 Biancone L, Pavia M, Del Vecchio Blanco G. et al . Hepatitis B and C virus infection in Crohn’s disease. Inflamm Bowel Dis. 2001; 7 287-294

Google Scholar
385 Bargiggia S, Thorburn D, Anderloni A. et al . Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther. 2005; 22 209-215

Google Scholar
386 Salcedo-Mora X, Mate J, Medina J. et al . Chronic hepatitis C and Crohn’s disease: nosocomial infection treatment with PEG-interferon plus ribavirin. Digestion. 2006; 73 210-214

Google Scholar
387 Tursi A. Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C. Inflamm Bowel Dis. 2007; 13 1189-1190

Google Scholar
388 Watanabe T, Inoue M, Harada K. et al . A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin. Gut. 2006; 55 1682-1683

Google Scholar
389 Abdelmalek M F, Liu C, Valentine J F. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn’s disease. Am J Gastroenterol. 2007; 102 1333-1334

Google Scholar
390 Citro V, Fristachi R, Tarantino G. Extensive psoriasis induced by pegylated interferon: a case report. J Med Case Reports. 2007; 1 86

Google Scholar
391 Tahara H, Kojima A, Hirokawa T. et al . Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C. Intern Med. 2007; 46 473-476

Google Scholar
392 Adla M, Downey K K, Ahmad J. Hepatic sarcoidosis associated with pegylated interferon alpha therapy for chronic hepatitis C: case report and review of literature. Dig Dis Sci. 2008; 53 2810-2812

Google Scholar
393 Schmidt K N, Ouyang W. Targeting interferon-alpha: a promising approach for systemic lupus erythematosus therapy. Lupus. 2004; 13 348-352

Google Scholar
394 Antonelli A, Ferri C, Fallahi P. et al . Thyroid disorders in chronic hepatitis C virus infection. Thyroid. 2006; 16 563-572

Google Scholar
395 Tomer Y, Blackard J T, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am. 2007; 36 1051-1066, x–xi

Google Scholar
396 Rodriguez-Torres M, Rios-Bedoya C F, Ortiz-Lasanta G. et al . Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis. Ann Hepatol. 2008; 7 72-77

Google Scholar
397 Papatheodoridis G V, Chrysanthos N, Savvas S. et al . Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat. 2006; 13 303-310

Google Scholar
398 Hui J M, Sud A, Farrell G C. et al . Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression (corrected). Gastroenterology. 2003; 125 1695-1704

Google Scholar
399 Mehta S H, Brancati F L, Strathdee S A. et al . Hepatitis C virus infection and incident type 2 diabetes. Hepatology. 2003; 38 50-56

Google Scholar
400 Shintani Y, Fujie H, Miyoshi H. et al . Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004; 126 840-848

Google Scholar
401 Wang C S, Wang S T, Yao W J. et al . Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol. 2007; 166 196-203

Google Scholar
402 Sjoberg K, Widell A, Verbaan H. Prevalence of hepatitis C in Swedish diabetics is low and comparable to that in health care workers. Eur J Gastroenterol Hepatol. 2008; 20 135-138

Google Scholar
403 Moucari R, Asselah T, Cazals-Hatem D. et al . Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008; 134 416-423

Google Scholar
404 Leandro G, Mangia A, Hui J. et al . Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006; 130 1636-1642

Google Scholar
405 Lecube A, Hernandez C, Simo R. et al . Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Am J Gastroenterol. 2007; 102 2189-2195

Google Scholar
406 Backus L I, Boothroyd D B, Phillips B R. et al . Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. 2007; 46 37-47

Google Scholar
407 Conjeevaram H S, Kleiner D E, Everhart J E. et al . Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007; 45 80-87

Google Scholar
408 Romero-Gomez M, Fernandez-Rodriguez C M, Andrade R J. et al . Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol. 2008; 48 721-727

Google Scholar
409 Kawaguchi T, Ide T, Taniguchi E. et al . Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007; 102 570-576

Google Scholar
410 Simo R, Lecube A, Genesca J. et al . Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care. 2006; 29 2462-2466

Google Scholar
411 d’Alteroche L, Majzoub S, Lecuyer A I. et al . Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis. J Hepatol. 2006; 44 56-61

Google Scholar
412 Hassan M, Hasan S, Giday S. et al . Hepatitis C virus in sickle cell disease. J Natl Med Assoc. 2003; 95 939-942

Google Scholar
413 Inati A, Taher A, Ghorra S. et al . Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. Br J Haematol. 2005; 130 644-646

Google Scholar
414 Butensky E, Pakbaz Z, Foote D. et al . Treatment of hepatitis C virus infection in thalassemia. Ann N Y Acad Sci. 2005; 1054 290-299

Google Scholar
415 Pistone G, Bertolini M C, Malaguarnera M. et al . Efficacy of interferon-based therapy in the treatment of thalassaemic patients with chronic hepatitis C: a meta-analysis. BioDrugs. 2000; 14 137-140

Google Scholar
416 Forton D M, Thomas H C, Murphy C A. et al . Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002; 35 433-439

Google Scholar
417 McAndrews M P, Farcnik K, Carlen P. et al . Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology. 2005; 41 801-808

Google Scholar
418 Cozzi A, Zignego A L, Carpendo R. et al . Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. J Viral Hepat. 2006; 13 402-408

Google Scholar
419 Schaefer M, Engelbrecht M A, Gut O. et al . Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26 731-746

Google Scholar
420 Asnis G M, De La Garza 2nd R, Miller A H. et al . Ribavirin may be an important factor in IFN-induced neuropsychiatric effects. J Clin Psychiatry. 2004; 65 581, author reply 581-582

Google Scholar
421 Kraus M R, Schafer A, Schottker K. et al . Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut. 2008; 57 531-536

Google Scholar
422 Kraus M R, Al-Taie O, Schafer A. et al . Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology. 2007; 132 1279-1286

Google Scholar
423 Anton C, Trifan A, Stanciu C. et al . Seizures during the treatment with interferon for chronic C hepatitis. Rev Med Chir Soc Med Nat Iasi. 2000; 104 135-137

Google Scholar
424 Seno H, Inagaki T, Itoga M. et al . A case of seizures 1 week after the cessation of interferon-alpha therapy. Psychiatry Clin Neurosci. 1999; 53 417-420

Google Scholar
425 Russo M W, Fried M W. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003; 124 1711-1719

Google Scholar
426 Morasco B J, Rifai M A, Loftis J M. et al . A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord. 2007; 103 83-90

Google Scholar
427 Schaefer M, Sarkar R, Spengler U. et al . Es-Citalopram for the prevention of PEG-IFN-alpha and ribavirin associated depression in HCV-infected patients without psychiatric risk factors (CIPPAD-study). Hepatology. 2008; 48 432A-433A

Google Scholar
428 Shiffman M L, Salvatore J, Hubbard S. et al . Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology. 2007; 46 371-379

Google Scholar
429 Younossi Z M, Nader F H, Bai C. et al . A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. J Viral Hepat. 2008; 15 370-378

Google Scholar
430 Afdhal N H, Dieterich D T, Pockros P J. et al . Epoetin alpha maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004; 126 1302-1311

Google Scholar
431 Pockros P J, Shiffman M L, Schiff E R. et al . Epoetin alpha improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004; 40 1450-1458

Google Scholar
432 Everson G T, Trotter J, Forman L. et al . Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005; 42 255-262

Google Scholar
433 Soza A, Everhart J E, Ghany M G. et al . Neutropenia during combination therapy of interferon alpha and ribavirin for chronic hepatitis C. Hepatology. 2002; 36 1273-1279

Google Scholar
434 Hauschild A, Kahler K C, Schafer M. et al . Interdisciplinary management recommendations for toxicity associated with interferon-alpha therapy. J Dtsch Dermatol Ges. 2008; 6 829-837, 829 – 838

Google Scholar
435 Fuhrmann V, Kramer L, Bauer E. et al . Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection. Dig Dis Sci. 2004; 49 1966-1970

Google Scholar
436 Hillier A E, Mand J, Raza A. et al . Consensus interferon induced interstitial pneumonitis in a patient with HCV. Am J Gastroenterol. 2006; 101 200-202

Google Scholar
437 Wolf Y, Haddad R, Jossipov J. et al . Alpha-interferon induced severe pneumonitis. J Toxicol Clin Toxicol. 1997; 35 113-114

Google Scholar
438 Carrillo-Esper R, Gonzalez-Avila D, Uribe-Rios M. et al . Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report. Ann Hepatol. 2008; 7 87-90

Google Scholar
439 Fattovich G, Giustina G, Degos F. et al . Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997; 112 463-472

Google Scholar
440 Planas R, Balleste B, Alvarez M A. et al . Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 2004; 40 823-830

Google Scholar
441 del O lmo JA, Pena A, Serra M A. et al . Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. J Hepatol. 2000; 32 19-24

Google Scholar
442 Gane E J, Portmann B C, Naoumov N V. et al . Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996; 334 815-820

Google Scholar
443 Watt K D, Burak K W, Deschenes M. et al . Survival after liver transplantation for hepatitis C is unchanged over two decades in Canada. Can J Gastroenterol. 2008; 22 153-154

Google Scholar
444 Forman L M, Lewis J D, Berlin J A. et al . The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002; 122 889-896

Google Scholar
445 Wiesner R, Edwards E. Mayo end-stage liver disease model (MELD) score predicts liver transplant wailting list mortality: Implication for liver allograft policy. Transplantation. 2001; 71 461

Google Scholar
446 Wiesner R, Edwards E, Freeman R. et al . Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003; 124 91-96

Google Scholar
447 Freeman R B. MELD: the holy grail of organ allocation?. J Hepatol. 2005; 42 16-20

Google Scholar
448 Mazzaferro V, Chun Y S, Poon R T. et al . Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008; 15 1001-1007

Google Scholar
449 Mazzaferro V, Regalia E, Doci R. et al . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334 693-699

Google Scholar
450 Yao F Y, Ferrell L, Bass N M. et al . Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33 1394-1403

Google Scholar
451 Yao F Y, Xiao L, Bass N M. et al . Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007; 7 2587-2596

Google Scholar
452 Decaens T, Roudot-Thoraval F, Hadni-Bresson S. et al . Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl. 2006; 12 1761-1769

Google Scholar
453 Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004; 240 451-459, discussion 459 – 461

Google Scholar
454 Saab S, Niho H, Comulada S. et al . Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis. Liver Int. 2005; 25 940-945

Google Scholar
455 Berenguer M, Ferrell L, Watson J. et al . HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000; 32 673-684

Google Scholar
456 Berenguer M, Prieto M, Palau A. et al . Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl. 2003; 9 228-235

Google Scholar
457 Berenguer M, Prieto M, Rayon J M. et al . Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000; 32 852-858

Google Scholar
458 Neff G W, O’Brien C B, Nery J. et al . Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl. 2004; 10 1497-1503

Google Scholar
459 Roayaie S, Schiano T D, Thung S N. et al . Results of retransplantation for recurrent hepatitis C. Hepatology. 2003; 38 1428-1436

Google Scholar
460 Rosen H R, Prieto M, Casanovas-Taltavull T. et al . Validation and Refinement of Survival Models for Liver Retransplantation. Hepatology. 2003; 38 460-469

Google Scholar
461 Yoo H Y, Maheshwari A, Thuluvath P J. Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome. Liver Transpl. 2003; 9 897-904

Google Scholar
462 Rosen H R, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation. 1998; 66 1612-1616

Google Scholar
463 Pelletier S J, Schaubel D E, Punch J D. et al . Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl. 2005; 11 434-440

Google Scholar
464 Ghabril M, Dickson R C, Machicao V I. et al . Liver retransplantation of patients with hepatitis C infection is associated with acceptable patient and graft survival. Liver Transpl. 2007; 13 1717-1727

Google Scholar
465 Ghabril M, Dickson R, Wiesner R. Improving outcomes of liver retransplantation: an analysis of trends and the impact of Hepatitis C infection. Am J Transplant. 2008; 8 404-411

Google Scholar
466 Bahra M, Neumann U P, Jacob D. et al . Outcome after liver re-transplantation in patients with recurrent chronic hepatitis C. Transpl Int. 2007; 20 771-778

Google Scholar
467 McCashland T, Watt K, Lyden E. et al . Retransplantation for hepatitis C: results of a UääS. multicenter retransplant study. Liver Transpl. 2007; 13 1246-1253

Google Scholar
468 Jain A, Orloff M, Abt P. et al . Survival outcome after hepatic retransplantation for hepatitis C virus-positive and -negative recipients. Transplant Proc. 2005; 37 3159-3161

Google Scholar
469 Charlton M. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis. 2003; 7 585-602

Google Scholar
470 Ghobrial R M. Retransplantation for recurrent hepatitis C. Liver Transpl. 2002; 8 S38-S43

Google Scholar
471 Burton J R, Sonnenberg Jr A, Rosen H R. Retransplantation for recurrent hepatitis C in the MELD era: maximizing utility. Liver Transpl. 2004; 10 S59-S64

Google Scholar
472 Burton J R, Rosen H R. Liver retransplantation for hepatitis C virus recurrence: a survey of liver transplant programs in the United States. Clin Gastroenterol Hepatol. 2005; 3 700-704

Google Scholar
473 McCashland T M. Retransplantation for recurrent hepatitis C: positive aspects. Liver Transpl. 2003; 9 S67-S72

Google Scholar
474 Rosen H R. Retransplantation for hepatitis C: implications of different policies. Liver Transpl. 2000; 6 S41-S46

Google Scholar
475 Watt K D, Lyden E R, McCashland T M. Poor survival after liver retransplantation: is hepatitis C to blame?. Liver Transpl. 2003; 9 1019-1024

Google Scholar
476 Carmiel-Haggai Jr M, Fiel M I, Gaddipati H C. et al . Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl. 2005; 11 1567-1573

Google Scholar
477 Rosen H R. Liver retransplantation for hepatitis C: seeing is believing. Liver Transpl. 2007; 13 1217-1218

Google Scholar
478 Thomas R M, Brems J J, Guzman-Hartman G. et al . Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl. 2003; 9 905-915

Google Scholar
479 Picciotto F P, Tritto G, Lanza A G. et al . Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007; 46 459-465

Google Scholar
480 Wiesner R H, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003; 9 S1-S9

Google Scholar
481 Bundesärztekammer . Bekanntmachungen: Richtlinien zur Organtransplantation gem. § 16 TPG. Dtsch Ärzteblatt. 2007; 104 A3282 /B-2858 /C-2738

Google Scholar
482 Ahmad J, Downey K K, Akoad M. et al . Impact of the MELD score on waiting time and disease severity in liver transplantation in United States veterans. Liver Transpl. 2007; 13 1564-1569

Google Scholar
483 Crippin J S, McCashland T, Terrault N. et al . A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002; 8 350-355

Google Scholar
484 Fattovich G, Stroffolini T, Zagni I. et al . Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127 S35-S50

Google Scholar
485 Daniele B, Bencivenga A, Megna A S. et al . Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004; 127 S108-S112

Google Scholar
486 Bruix J, Sherman M, Llovet J M. et al . Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35 421-430

Google Scholar
487 Ballardini G, De Raffele E, Groff P. et al . Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl. 2002; 8 10-20

Google Scholar
488 Greenson J K, Svoboda-Newman S M, Merion R M. et al . Histologic progression of recurrent hepatitis C in liver transplant allografts. The American journal of surgical pathology. 1996; 20 731-738

Google Scholar
489 Guido M, Fagiuoli S, Tessari G. et al . Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut. 2002; 50 697-700

Google Scholar
490 Baiocchi L, Tisone G, Palmieri G. et al . Hepatic steatosis: a specific sign of hepatitis C reinfection after liver transplantation. Liver Transpl Surg. 1998; 4 441-447

Google Scholar
491 Pelletier S J, Iezzoni J C, Crabtree T D. et al . Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl. 2000; 6 44-53

Google Scholar
492 Samuel D, Forns X, Berenguer M. et al . Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12 – 14, 2006). J Hepatol. 2006; 45 127-143

Google Scholar
493 Taga S A, Washington M K, Terrault N. et al . Cholestatic hepatitis C in liver allografts. Liver Transpl Surg. 1998; 4 304-310

Google Scholar
494 Dixon L R, Crawford J M. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl. 2007; 13 219-226

Google Scholar
495 Davies S E, Portmann B C, O’Grady J G. et al . Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 1991; 13 150-157

Google Scholar
496 Terrault N A, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 2006; 12 1192-1204

Google Scholar
497 Gish R G, Afdhal N H, Dieterich D T. et al . Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol. 2005; 3 311-318

Google Scholar
498 Wright T L, Donegan E, Hsu H H. et al . Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 1992; 103 317-322

Google Scholar
499 Garcia-Retortillo M, Forns X, Feliu A. et al . Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002; 35 680-687

Google Scholar
500 McCaughan G W, Omata M, Amarapurkar D. et al . Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007; 22 615-633

Google Scholar
501 Berenguer M. Recurrent hepatitis C: worse outcomes established, interventions still inadequate. Liver Transpl. 2007; 13 641-643

Google Scholar
502 Belli L S, Burroughs A K, Burra P. et al . Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl. 2007; 13 733-740

Google Scholar
503 Berenguer M, Crippin J, Gish R. et al . A model to predict severe HCV-related disease following liver transplantation. Hepatology. 2003; 38 34-41

Google Scholar
504 Iacob S, Cicinnati V R, Hilgard P. et al . Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation. 2007; 84 56-63

Google Scholar
505 Condron S L, Heneghan M A, Patel K. et al . Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection. Transplantation. 2005; 80 145-148

Google Scholar
506 Wali M, Harrison R F, Gow P J. et al . Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut. 2002; 51 248-252

Google Scholar
507 Di Martino V, Saurini F, Samuel D. et al . Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology. 1997; 26 1343-1350

Google Scholar
508 Berenguer M, Aguilera V, Prieto M. et al . Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl. 2006; 12 762-767

Google Scholar
509 Martin P, Busuttil R W, Goldstein R M. et al . Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl. 2004; 10 1258-1262

Google Scholar
510 Wiesner R H. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK 506 Study Group. Transplantation. 1998; 66 493-499

Google Scholar
511 Zervos X A, Weppler D, Fragulidis G P. et al . Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation. 1998; 65 1044-1046

Google Scholar
512 Nakagawa M, Sakamoto N, Tanabe Y. et al . Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology. 2005; 129 1031-1041

Google Scholar
513 Fernandes F, Poole D S, Hoover S. et al . Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS 5A and NS 5B. Hepatology. 2007; 46 1026-1033

Google Scholar
514 Hilgard P, Kahraman A, Lehmann N. et al . Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis. World J Gastroenterol. 2006; 12 697-702

Google Scholar
515 Zekry A, Gleeson M, Guney S. et al . A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl. 2004; 10 52-57

Google Scholar
516 Wiesner R H, Shorr J S, Steffen B J. et al . Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl. 2005; 11 750-759

Google Scholar
517 Firpi R J, Nelson D R, Davis G L. Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl. 2003; 9 57-61

Google Scholar
518 Samonakis D N, Cholongitas E, Triantos C K. et al . Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol. 2005; 43 1091-1093

Google Scholar
519 Schacherer D, Zeitoun M, Buttner R. et al . Sirolimus-induced drug fever and ciclosporin-induced leukencephalopathia with seizures in one liver transplant recipient. World J Gastroenterol. 2007; 13 6090-6093

Google Scholar
520 Nelson D R, Soldevila-Pico C, Reed A. et al . Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl. 2001; 7 1064-1070

Google Scholar
521 Calmus Y, Scheele J R, Gonzalez-Pinto I. et al . Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl. 2002; 8 123-131

Google Scholar
522 Neuhaus P, Clavien P A, Kittur D. et al . Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl. 2002; 8 132-142

Google Scholar
523 Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg. 1999; 5 S107-S114

Google Scholar
524 Sheiner P A, Schwartz M E, Mor E. et al . Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology. 1995; 21 30-34

Google Scholar
525 Berenguer M, Prieto M, Cordoba J. et al . Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol. 1998; 28 756-763

Google Scholar
526 Rosen H R, Shackleton C R, Higa L. et al . Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol. 1997; 92 1453-1457

Google Scholar
527 Kato T, Gaynor J J, Yoshida H. et al . Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation. 2007; 84 829-835

Google Scholar
528 Segev D L, Sozio S M, Shin E J. et al . Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl. 2008; 14 512-525

Google Scholar
529 Vivarelli M, Burra P, La Barba G. et al . Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol. 2007; 47 793-798

Google Scholar
530 Brillanti S, Vivarelli M, De Ruvo N. et al . Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl. 2002; 8 884-888

Google Scholar
531 Berenguer M, Aguilera V, Prieto M. et al . Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol. 2006; 44 717-722

Google Scholar
532 Shergill A K, Khalili M, Straley S. et al . Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant. 2005; 5 118-124

Google Scholar
533 Sugawara Y, Makuuchi M, Matsui Y. et al . Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation. 2004; 78 1308-1311

Google Scholar
534 Sheiner P A, Boros P, Klion F M. et al . The efficacy of prophylactic interferon alpha-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology. 1998; 28 831-838

Google Scholar
535 Singh N, Gayowski T, Wannstedt C F. et al . Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation. 1998; 65 82-86

Google Scholar
536 Chalasani N, Manzarbeitia C, Ferenci P. et al . Peginterferon alpha-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology. 2005; 41 289-298

Google Scholar
537 Berenguer M, Palau A, Aguilera V. et al . Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008; 8 679-687

Google Scholar
538 Abdelmalek M F, Firpi R J, Soldevila-Pico C. et al . Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2004; 10 199-207

Google Scholar
539 Giostra E, Kullak-Ublick G A, Keller W. et al . Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int. 2004; 17 169-176

Google Scholar
540 Bizollon T, Ahmed S N, Radenne S. et al . Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut. 2003; 52 283-287

Google Scholar
541 Castells L, Vargas V, Allende H. et al . Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol. 2005; 43 53-59

Google Scholar
542 Toniutto P, Fabris C, Fumo E. et al . Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. J Gastroenterol Hepatol. 2005; 20 577-582

Google Scholar
543 Neff G W, Montalbano M, O’Brien C B. et al . Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alpha-2b and ribavirin therapy. Transplantation. 2004; 78 1303-1307

Google Scholar
544 Dumortier J, Scoazec J Y, Chevallier P. et al . Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alpha-2b and ribavirin combination. J Hepatol. 2004; 40 669-674

Google Scholar
545 Samuel D, Bizollon T, Feray C. et al . Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology. 2003; 124 642-650

Google Scholar
546 Berenguer M, Palau A, Fernandez A. et al . Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2006; 12 1067-1076

Google Scholar
547 Cicinnati V R, Iacob S, Klein C G. et al . Ribavirin with either standard or pegylated interferon to treat recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther. 2007; 26 291-303

Google Scholar
548 Gane E J, Lo S K, Riordan S M. et al . A randomized study comparing ribavirin and interferon alpha monotherapy for hepatitis C recurrence after liver transplantation. Hepatology. 1998; 27 1403-1407

Google Scholar
549 Kizilisik T A, al-Sebayel M, Hammad A. et al . Hepatitis C recurrence in liver transplant recipients. Transplant Proc. 1997; 29 2875-2877

Google Scholar
550 Ghalib R, Pandula R, Kadhim T. et al . Treatment of recurrent hepatitis C after liver transplantationwith alpha-2b interferon plus ribavirin. Hepatology. 2000; 32 291A

Google Scholar
551 Stanca C M, Fiel M I, Kontorinis N. et al . Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alpha-2a and ribavirin. Transplantation. 2007; 84 180-186

Google Scholar
552 Tugwell B D, Patel P R, Williams I T. et al . Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor. Ann Intern Med. 2005; 143 648-654

Google Scholar
553 File E, Mehra M, Nair S. et al . Allograft transmission of hepatitis C virus infection from infected donors in cardiac transplantation. Transplantation. 2003; 76 1096-1100

Google Scholar
554 Watanabe T, Koyama I, Shinozuka N. et al . A case of renal transplantation received from a living donor with second-generation anti-hepatitis C virus antibody positive into an anti-hepatitis C virus antibody negative recipient. Transplant Proc. 2000; 32 1593-1594

Google Scholar
555 Ricchiuti A, Brunati A, Mirabella S. et al . Use of hepatitis C virus-positive grafts in liver transplantation: a single-centre experience. Transplant Proc. 2005; 37 2569-2570

Google Scholar
556 Vargas H E, Laskus T, Wang L F. et al . Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology. 1999; 117 149-153

Google Scholar
557 Velidedeoglu E, Desai N M, Campos L. et al . The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation. 2002; 73 582-587

Google Scholar
558 Saab S, Chang A J, Comulada S. et al . Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl. 2003; 9 1053-1061

Google Scholar
559 Kasprzyk T, Kwiatkowski A, Wszola M. et al . Long-term results of kidney transplantation from HCV-positive donors. Transplant Proc. 2007; 39 2701-2703

Google Scholar
560 Khapra A P, Agarwal K, Fiel M I. et al . Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV + allografts. Liver Transpl. 2006; 12 1496-1503

Google Scholar
561 Marroquin C E, Marino G, Kuo P C. et al . Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl. 2001; 7 762-768

Google Scholar
562 Mandal A K, Kraus E S, Samaniego M. et al . Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant. 2000; 14 391-396

Google Scholar
563 Woodside K J, Ishihara K, Theisen J E. et al . Use of kidneys from hepatitis C seropositive donors shortens waitlist time but does not alter one-yr outcome. Clin Transplant. 2003; 17 433-437

Google Scholar
564 Veroux P, Veroux M, Puliatti C. et al . Kidney transplantation from hepatitis C virus-positive donors into hepatitis C virus-positive recipients: a safe way to expand the donor pool?. Transplant Proc. 2005; 37 2571-2573

Google Scholar
565 Ridruejo E, Cusumano A, Diaz C. et al . Hepatitis C virus infection and outcome of renal transplantation. Transplant Proc. 2007; 39 3127-3130

Google Scholar
566 Gasink L B, Blumberg E A, Localio A R. et al . Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA. 2006; 296 1843-1850

Google Scholar
567 Wang S S, Chou N K, Ko W J. et al . Heart transplantation using donors positive for hepatitis. Transplant Proc. 2004; 36 2371-2373

Google Scholar
568 Firpi R J, Nelson D R. Viral hepatitis: manifestations and management strategy. Hematology Am Soc Hematol Educ Program. 2006; 375-380

Google Scholar
569 Zekri A R, Mohamed W S, Samra M A. et al . Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transpl Immunol. 2004; 13 305-311

Google Scholar
570 Peffault de Latour R, Levy V, Asselah T. et al . Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004; 103 1618-1624

Google Scholar
571 Ivantes C A, Amarante H, Ioshii S O. et al . Hepatitis C virus in long-term bone marrow transplant survivors. Bone Marrow Transplant. 2004; 33 1181-1185

Google Scholar
572 Ghobrial R M, Steadman R, Gornbein J. et al . A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg. 2001; 234 384-393, discussion 393 – 384

Google Scholar
573 Gudmundsson G S, Malinowska K, Robinson J A. et al . Five-year follow-up of hepatitis C-naive heart transplant recipients who received hepatitis C-positive donor hearts. Transplant Proc. 2003; 35 1536-1538

Google Scholar
574 Testa G, Goldstein R M, Netto G. et al . Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation. 1998; 65 925-929

Google Scholar
575 Weclawiack H, Kamar N, Mehrenberger M. et al . Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. Nephrol Dial Transplant. 2008; 23 1043-1047

Google Scholar
576 Peffault de Latour R, Asselah T, Levy V. et al . Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 2005; 36 709-713

Google Scholar
577 Schmitz V, Kiessling A, Bahra M. et al . Peginterferon alpha-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann Transplant. 2007; 12 22-27

Google Scholar
578 Terrault N A, Adey D B. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol. 2007; 2 563-575

Google Scholar
579 Luciani G, Bossola M, Muscaritoli M. et al . Sustained response with negative serum HCV-mRNA and disappearance of antibodies after interferon-alpha therapy in a kidney transplant recipient with chronic active viral hepatitis C. J Nephrol. 2003; 16 417-420

Google Scholar
580 Shu K H, Lan J L, Wu M J. et al . Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation. 2004; 77 1894-1896

Google Scholar
581 Baid S, Tolkoff-Rubin N, Saidman S. et al . Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant. 2003; 3 74-78

Google Scholar
582 Fagiuoli S, Pevere S, Minniti F. et al . Natural leukocyte interferon alpha for the treatment of chronic viral hepatitis in heart transplant recipients. Transplantation. 2003; 75 982-986

Google Scholar
583 Chu C M, Yeh C T, Liaw Y F. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut. 1999; 45 613-617

Google Scholar
584 Liaw Y F, Chen Y C, Sheen I S. et al . Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology. 2004; 126 1024-1029

Google Scholar
585 Sagnelli E, Pasquale G, Coppola N. et al . Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection. 2004; 32 144-148

Google Scholar
586 Zarski J P, Bohn B, Bastie A. et al . Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998; 28 27-33

Google Scholar
587 Chen Y C, Sheen I S, Chu C M. et al . Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002; 123 1084-1089

Google Scholar
588 Ilan Y, Ashur Y, Tur-Kaspa R. et al . Chronic hepatitis C virus infection with exposure to hepatitis B virus. Isr J Med Sci. 1994; 30 259-263

Google Scholar
589 Benvegnu L, Fattovich G, Noventa F. et al . Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer. 1994; 74 2442-2448

Google Scholar
590 Yao F Y. Should surveillance for hepatocellular carcinoma be increased in patients with cirrhosis and small liver nodules?. Nat Clin Pract Gastroenterol Hepatol. 2006; 3 544-545

Google Scholar
591 Raffa G, Maimone S, Cargnel A. et al . Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS. 2007; 21 2171-2175

Google Scholar
592 Rodriguez-Torres M, Gonzalez-Garcia J, Brau N. et al . Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem?. J Med Virol. 2007; 79 694-700

Google Scholar
593 Cacciola I, Pollicino T, Squadrito G. et al . Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999; 341 22-26

Google Scholar
594 De Maria N, Colantoni A, Friedlander L. et al . The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol. 2000; 95 3529-3536

Google Scholar
595 Hui C K, Lau E, Wu H. et al . Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. J Clin Virol. 2006; 35 185-192

Google Scholar
596 Pollicino T, Squadrito G, Cerenzia G. et al . Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004; 126 102-110

Google Scholar
597 Miura Y, Shibuya A, Adachi S. et al . Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatol Res. 2008; 38 546-556

Google Scholar
598 Hasegawa I, Orito E, Tanaka Y. et al . Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. Liver Int. 2005; 25 247-253

Google Scholar
599 Mrani S, Chemin I, Menouar K. et al . Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol. 2007; 79 1075-1081

Google Scholar
600 Eyster M E, Diamondstone L S, Lien J M. et al . Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr. 1993; 6 602-610

Google Scholar
601 Rockstroh J K, Spengler U, Sudhop T. et al . Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol. 1996; 91 2563-2568

Google Scholar
602 Soto B, Sanchez-Quijano A, Rodrigo L. et al . Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997; 26 1-5

Google Scholar
603 Sanchez-Quijano A, Andreu J, Gavilan F. et al . Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis. 1995; 14 949-953

Google Scholar
604 Darby S C, Ewart D W, Giangrande P L. et al . Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors’ Organisation. Lancet. 1997; 350 1425-1431

Google Scholar
605 Poynard T, Mathurin P, Lai C L. et al . A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003; 38 257-265

Google Scholar
606 Diaz-Sanchez A, Matilla A, Nunez O. et al . HIV-infected patients with hepatocellular carcinoma have worse survival prognosis than uninfected patients adjusted by BCLC stage. Hepatology. 2007; 46 401A

Google Scholar
607 Greub G, Ledergerber B, Battegay M. et al . Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000; 356 1800-1805

Google Scholar
608 Rockstroh J, Konopnicki D, Soriano V. et al .Hepatitis B and hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS, progression and response to HAART. 11th Conference on Retroviruses and Opportunistic Infectio. San Francisco; 2004: 799

Google Scholar
609 Sulkowski M S, Moore R D, Mehta S H. et al . Hepatitis C and progression of HIV disease. JAMA. 2002; 288 199-206

Google Scholar
610 Kaufmann G R, Perrin L, Pantaleo G. et al . CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003; 163 2187-2195

Google Scholar
611 Zylberberg H, Pialoux G, Carnot F. et al . Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis. 1998; 27 1255-1258

Google Scholar
612 Perez-Olmeda M, Garcia-Samaniego J, Soriano V. Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy. AIDS. 2000; 14 212

Google Scholar
613 Chung R T, Evans S R, Yang Y. et al . Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS. 2002; 16 1915-1923

Google Scholar
614 Fialaire P, Payan C, Vitour D. et al . Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J Infect Dis. 1999; 180 574-575

Google Scholar
615 Benhamou Y, Di Martino V, Bochet M. et al . Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology. 2001; 34 283-287

Google Scholar
616 Pineda J A, Garcia-Garcia J A, Aguilar-Guisado M. et al . Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology. 2007; 46 622-630

Google Scholar
617 Qurishi N, Kreuzberg C, Luchters G. et al . Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003; 362 1708-1713

Google Scholar
618 Martin-Carbonero L, Benhamou Y, Puoti M. et al . Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis. 2004; 38 128-133

Google Scholar
619 Saves M, Vandentorren S, Daucourt V. et al . Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996 – 1998. Groupe d’Epidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS. 1999; 13 F115-F121

Google Scholar
620 den Brinker M, Wit F W, Wertheim-Dillen P M. et al . Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000; 14 2895-2902

Google Scholar
621 Martinez van E, Blanco J L, Arnaiz J A. et al . Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001; 15 1261-1268

Google Scholar
622 Sulkowski M S, Thomas D L, Chaisson R E. et al . Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000; 283 74-80

Google Scholar
623 Dieterich D T, Robinson P A, Love J. et al . Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis. 2004; 38 (Suppl 2) S80-S89

Google Scholar
624 Sulkowski M, Mehta S, Moore R. Population prevalence of hepatic steatosis among antiretroviral experienced HCV/HIV-coinfected adults with and without stavudine exposure. 11th Conference on Retroviruses and Opportunistic Infections. 2004; February 8 – 11 Abstract 72

Google Scholar
625 Montessori V, Harris M, Montaner J S. Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Semin Liver Dis. 2003; 23 167-172

Google Scholar
626 Ghosn J, Pierre-Francois S, Thibault V. et al . Acute hepatitis C in HIV-infected men who have sex with men. HIV Med. 2004; 5 303-306

Google Scholar
627 Coutinho R, Thijs van de Laar R. Rise in HCV incidence in HIV-infected men who have sex with men in Amsterdam: sexual transmission of difficult-to-treat HCV genotypes 1 and 4. 13th Conference on Retroviruses and Opportunistic Infections. 2006; Denver abstract 87

Google Scholar
628 Luetkemeyer A, Hare C B, Stansell J. et al . Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr. 2006; 41 31-36

Google Scholar
629 Micallef J M, Kaldor J M, Dore G J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006; 13 34-41

Google Scholar
630 Thomas D L, Astemborski J, Rai R M. et al . The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000; 284 450-456

Google Scholar
631 Dominguez S, Ghosn J, Valantin M A. et al . Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS. 2006; 20 1157-1161

Google Scholar
632 Kamal S M, Fouly A E, Kamel R R. et al . Peginterferon alpha-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology. 2006; 130 632-638

Google Scholar
633 Vogel M, Bieniek B, Jessen H. et al . Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat. 2005; 12 207-211

Google Scholar
634 Vogel M, Baumgarten A, Klausen G. et al . Pegylated interferon in the treatment of acute HCV infection in HIV + individuals: interim analysis of a large German multicenter study. 2nd International Workshop on HIV and Viral Hepatitis Co-Infection. 2006; Amsterdam abstract 25

Google Scholar
635 Gilleece Y C, Browne R E, Asboe D. et al . Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr. 2005; 40 41-46

Google Scholar
636 Vogel M, Baumgarten A, Klausen G. et al .Predictive factors in the treatment of acute HCV-infection in HIV positive individuals: interim analysis of a large German multicenter study. 10th European AIDS Conference Dublin 2005

Google Scholar
637 Vogel M, Nattermann J, Baumgarten A. et al . Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther. 2006; 11 1097-1101

Google Scholar
638 Chuang W L, Dai C Y, Chang W Y. et al . Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther. 2005; 10 125-133

Google Scholar
639 Fukuda R, Ishimura N, Kushiyama Y. et al . Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J Hepatol. 1997; 26 455-461

Google Scholar
640 Weltman M D, Brotodihardjo A, Crewe E B. et al . Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat. 1995; 2 39-45

Google Scholar
641 Zignego A L, Fontana R, Puliti S. et al . Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. Arch Virol. 1997; 142 535-544

Google Scholar
642 Villa E, Grottola A, Buttafoco P. et al . High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol. 2001; 96 2973-2977

Google Scholar
643 Potthoff A, Wedemeyer H, Boecher W O. et al . The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol. 2008; 49 688-694

Google Scholar
644 Jardi R, Rodriguez F, Buti M. et al . Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology. 2001; 34 404-410

Google Scholar
645 Liaw Y F, Tsai S L, Sheen I S. et al . Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. Am J Gastroenterol. 1998; 93 354-359

Google Scholar
646 Mathurin P, Thibault V, Kadidja K. et al . Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J Viral Hepat. 2000; 7 15-22

Google Scholar
647 Pontisso P, Ruvoletto M G, Fattovich G. et al . Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology. 1993; 105 1529-1533

Google Scholar
648 Sagnelli E, Coppola N, Scolastico C. et al . Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology. 2000; 32 1106-1110

Google Scholar
649 Landau A, Batisse D, Piketty C. et al . Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS. 2001; 15 2149-2155

Google Scholar
650 Sauleda S, Juarez A, Esteban J I. et al . Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology. 2001; 34 1035-1040

Google Scholar
651 Bochet M, De Torres M, Valentin M. Efficacy and tolerance of interferon-alpha plus ribavirin for chronic hepatitis C in HIV-infected patients. 8th Conference on Retroviruses and Opportunistic Infections Chicago; 2001: 574

Google Scholar
652 Nasti G, Di Gennaro G, Tavio M. et al . Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alpha-2b and tribavirin. AIDS. 2001; 15 1783-1787

Google Scholar
653 Perez-Olmeda M, Nunez M, Romero M. et al . Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS. 2003; 17 1023-1028

Google Scholar
654 Voigt E, Schulz C, Mauss S. et al .Factors related to outcome of treatment with pegylated interferon-alpha 2a (PEG-INF) + ribavirin (RBV) in HCV/HIV-coinfected patients. 2nd IAS Conference on HIV Pathogenesis and Treatment Paris; 2003: 976

Google Scholar
655 Torriani F J, Rodriguez-Torres M, Rockstroh J K. et al . Peginterferon Alpha-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004; 351 438-450

Google Scholar
656 Carrat F, Bani-Sadr F, Pol S. et al . Pegylated interferon alpha-2b vs standard interferon alpha-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004; 292 2839-2848

Google Scholar
657 Chung R T, Andersen J, Volberding P. et al . Peginterferon Alpha-2a plus ribavirin versus interferon alpha-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004; 351 451-459

Google Scholar
658 Moreno L, Quereda C, Moreno A. et al . Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS. 2004; 18 67-73

Google Scholar
659 Laguno M, Murillas J, Blanco J L. et al . Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004; 18 F27-F36

Google Scholar
660 Nunez M, Miralles C, Berdun M A. et al . Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007; 23 972-982

Google Scholar
661 Puoti M, Zanini B, Luca de A. et al .Results of randomized controlled trial on the impact of prolonged combination anti-HCV treatment on relapse rate in HIV/HCV-coinfected patients: the ROMANCE trial. Program and abstracts of the 3 rd International Workshop on HIV and Hepatitis Coinfection Paris; France 7.–9.6.2007 Abstract 1

Google Scholar
662 Mauss S, Valenti W, DePamphilis J. et al . Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS. 2004; 18 F21-F25

Google Scholar
663 Patton H M, Patel K, Behling C. et al . The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004; 40 484-490

Google Scholar
664 Castera L, Chouteau P, Hezode C. et al . Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol. 2005; 100 711-715

Google Scholar
665 Kaserer K, Fiedler R, Steindl P. et al . Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. Histopathology. 1998; 32 454-461

Google Scholar
666 Sulkowski M S, Mehta S H, Torbenson M. et al . Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS. 2005; 19 585-592

Google Scholar
667 Uberti-Foppa C, De Bona A, Morsica G. et al . Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr. 2003; 33 146-152

Google Scholar
668 Gisolf E H, Dreezen C, Danner S A. et al . Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis. 2000; 31 1234-1239

Google Scholar
669 Ormseth E J, Holtzmuller K C, Goodman Z D. et al . Hepatic decompensation associated with lamivudine: a case report and review of lamivudine-induced hepatotoxicity. Am J Gastroenterol. 2001; 96 1619-1622

Google Scholar
670 ter Hofstede H J, Marie de S, Foudraine N A. et al . Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS. 2000; 11 611-616

Google Scholar
671 Lai K K, Gang D L, Zawacki J K. et al . Fulminant hepatic failure associated with 2’,3’-dideoxyinosine (ddI). Ann Intern Med. 1991; 115 283-284

Google Scholar
672 Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet. 2001; 357 280-281

Google Scholar
673 Salmon-Ceron D, Chauvelot-Moachon L, Abad S. et al . Mitochondrial toxic effects and ribavirin. Lancet. 2001; 357 1803-1804

Google Scholar
674 Opravil M, Sasadeusz J, Cooper D A. et al . Effect of baseline CD 4 cell count on the efficacy and safety of peginterferon Alpha-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr. 2008; 47 36-49

Google Scholar
675 Brau N, Rodriguez-Torres M, Prokupek D. et al . Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b + full-course vs. 16-week delayed ribavirin. Hepatology. 2004; 39 989-998

Google Scholar
676 Sulkowski M S, Dieterich D T, Bini E J. et al . Epoetin alpha once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr. 2005; 39 504-506

Google Scholar
677 Bani-Sadr F, Denoeud L, Morand P. et al . Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?. J Acquir Immune Defic Syndr. 2007; 45 123-125

Google Scholar
678 John M, Flexman J, French M A. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?. AIDS. 1998; 12 2289-2293

Google Scholar
679 Torti C, Lapadula G, Casari S. et al . Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis. 2005; 5 58

Google Scholar
680 Rutschmann O T, Negro F, Hirschel B. et al . Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis. 1998; 177 783-785

Google Scholar
681 Nunez M, Rios P, Martin-Carbonero L. et al . Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr. 2002; 30 65-68

Google Scholar
682 Zylberberg H, Chaix M L, Rabian C. et al . Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. Clin Infect Dis. 1998; 26 1104-1106

Google Scholar
683 Martin-Carbonero L, Nunez M, Rios P. et al . Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. AIDS. 2002; 16 1423-1425

Google Scholar
684 Prachalias A A, Pozniak A, Taylor C. et al . Liver transplantation in adults coinfected with HIV. Transplantation. 2001; 72 1684-1688

Google Scholar
685 Neff G W, Bonham A, Tzakis A G. et al . Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl. 2003; 9 239-247

Google Scholar
686 Ragni M V, Belle S H, Im K. et al . Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis. 2003; 188 1412-1420

Google Scholar
687 Samuel D, Duclos Vallee J C, Teicher E. et al . Liver transplantation in patients with HIV infection. J Hepatol. 2003; 39 3-6

Google Scholar
688 Duclos-Vallee J C, Vittecoq D, Teicher E. et al . Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients. J Hepatol. 2005; 42 341-349

Google Scholar
689 Norris S, Taylor C, Muiesan P. et al . Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl. 2004; 10 1271-1278

Google Scholar
690 Radecke K, Fruhauf N R, Miller M. et al . Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis. Liver Int. 2005; 25 101-108

Google Scholar
691 Vogel M, Voigt E, Schafer N. et al . Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort. Liver Transpl. 2005; 11 1515-1521

Google Scholar
692 Moreno S, Fortun J, Quereda C. et al . Liver transplantation in HIV-infected recipients. Liver Transpl. 2005; 11 76-81

Google Scholar
693 Castells L, Escartin A, Bilbao I. et al . Liver transplantation in HIV-HCV coinfected patients: a case-control study. Transplantation. 2007; 83 354-358

Google Scholar
694 Schreibman I, Gaynor J J, Jayaweera D. et al . Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation. 2007; 84 697-705

Google Scholar
695 Vera M E, Dvorchik de I, Tom K. et al . Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant. 2006; 6 2983-2993

Google Scholar
696 Duclos-Vallee J C, Feray C, Sebagh M. et al . Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2008; 47 407-417

Google Scholar
697 Pineda J A, Romero-Gomez M, Diaz-Garcia F. et al . HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005; 41 779-789

Google Scholar
698 Ragni M V, Eghtesad B, Schlesinger K W. et al . Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl. 2005; 11 1425-1430

Google Scholar
699 Stock P G. Rapid deterioration of HIV co-infected patients waiting for liver transplantation is not predicted by MELD. Liver Transpl. 2005; 11 1315-1317

Google Scholar
700 Vogel M, Voigt E, Michaelis H C. et al . Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl. 2004; 10 939-944

Google Scholar
701 Di Martino V, Rufat P, Boyer N. et al . The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001; 34 1193-1199

Google Scholar
702 Watashi K, Hijikata M, Hosaka M. et al . Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology. 2003; 38 1282-1288

Google Scholar
703 Watashi K, Ishii N, Hijikata M. et al . Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell. 2005; 19 111-122

Google Scholar
704 Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl. 2007; 13 21-29

Google Scholar
705 Bhagat V, Foont J A, Schiff E R. et al . Spontaneous clearance of hepatitis C virus after liver transplantation in two patients coinfected with hepatitis C virus and human immunodeficiency virus. Liver Transpl. 2008; 14 92-95

Google Scholar
706 Wojcik K, Vogel M, Voigt E. et al . Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort. AIDS. 2007; 21 1363-1365

Google Scholar
707 Castells L, Esteban J I, Bilbao I. et al . Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. Antivir Ther. 2006; 11 1061-1070

Google Scholar
708 Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand Juli 2007. Epidemiologisches Bulletin. 2007; 50 267-286

Google Scholar
709 Laurence J C. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med. 2005; 118 (Suppl 10A) 75S-83S

Google Scholar
710 Collier A C, Corey L, Murphy V L. et al . Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med. 1988; 109 101-105

Google Scholar
711 Keet I P, Doornum van G, Safary A. et al . Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS. 1992; 6 509-510

Google Scholar
712 Rey D, Krantz V, Partisani M. et al . Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine. 2000; 18 1161-1165

Google Scholar
713 Overton E T, Sungkanuparph S, Powderly W G. et al . Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis. 2005; 41 1045-1048

Google Scholar
714 Fonseca M O, Pang L W, Paula Cavalheiro de N. et al . Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine. 2005; 23 2902-2908

Google Scholar
715 Cornejo P, Volkow P, Escobedo K. et al . Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS Res Ther. 2006; 3 9

Google Scholar
716 Altfeld M, Rockstroh J K, Addo M. et al . Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol. 1998; 29 306-309

Google Scholar
717 Sjogren M H. Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination. Am J Med. 2005; 118 Suppl 10A 34S-39S

Google Scholar
718 Gerner P, Wirth S, Wintermeyer P. et al . Prevalence of hepatitis C virus infection in children admitted to an urban hospital. J Infect. 2006; 52 305-308

Google Scholar
719 Schreier E, Höhne M. Hepatitis C – Epidemiologie und Prävention. Bundesgesundheitsbl. 2001; 44 7

Google Scholar
720 Bortolotti F, Iorio R, Resti M. et al . Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. J Hepatol. 2007; 46 783-790

Google Scholar
721 England K, Thorne C, Newell M L. Vertically acquired paediatric coinfection with HIV and hepatitis C virus. Lancet Infect Dis. 2006; 6 83-90

Google Scholar
722 Davison S M, Mieli-Vergani G, Sira J. et al . Perinatal hepatitis C virus infection: diagnosis and management. Arch Dis Child. 2006; 91 781-785

Google Scholar
723 Polywka S, Schroter M, Feucht H H. et al . Low risk of vertical transmission of hepatitis C virus by breast milk. Clin Infect Dis. 1999; 29 1327-1329

Google Scholar
724 Bortolotti F, Guido M, Zancan L. et al . Long-term outcome of hepatitis C in children. Hepatology. 2004; 39 1455, author reply 1455-1456

Google Scholar
725 Broide E, Kimchi N A, Scapa E. Chronic hepatitis C infection in children. Minerva Gastroenterol Dietol. 2006; 52 187-193

Google Scholar
726 Goodman Z D, Makhlouf H R, Liu L. et al . Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology. 2008; 47 836-843

Google Scholar
727 Rerksuppaphol S, Hardikar W, Dore G J. Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J Gastroenterol Hepatol. 2004; 19 1357-1362

Google Scholar
728 Barshes N R, Udell I W, Lee T C. et al . The natural history of hepatitis C virus in pediatric liver transplant recipients. Liver Transpl. 2006; 12 1119-1123

Google Scholar
729 Bortolotti F, Iorio R, Nebbia G. et al . Interferon treatment in children with chronic hepatitis C: long-lasting remission in responders, and risk for disease progression in non-responders. Dig Liver Dis. 2005; 37 336-341

Google Scholar
730 Rumbo C, Fawaz R L, Emre S H. et al . Hepatitis C in children: a quaternary referral center perspective. J Pediatr Gastroenterol Nutr. 2006; 43 209-216

Google Scholar
731 Iorio R, Giannattasio A, Sepe A. et al . Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis. 2005; 41 1431-1437

Google Scholar
732 Zuccotti G V, Torcoletti M, Salvini F. et al . Infants vertically infected with hepatitis C: a long term longitudinal follow-up. Pediatr Med Chir. 2004; 26 50-52

Google Scholar
733 Slowik M K, Jhaveri R. Hepatitis B and C viruses in infants and young children. Semin Pediatr Infect Dis. 2005; 16 296-305

Google Scholar
734 Wirth S, Ribes-Koninckx C, Bortolotti F. et al . Children with HIV infection show high sustained virological response rates on PegInterferon alpha-2b plus Ribavirin treatment. Hepatology. 2008; 48 392A-393A

Google Scholar
735 Wirth S, Pieper-Boustani H, Lang T. et al . Peginterferon alpha-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology. 2005; 41 1013-1018

Google Scholar
736 Kelly D, Haber B, Gonzalez-Peralta R P. et al . Sustained virologic response to interferon alpha-2b plus ribavirin predicts long-term clearance of HCV in pediatric patients at 5-year follow-up. J Hepatol. 2008; S298 800

Google Scholar
737 Schwarz K B, Gonzalez-Peralta R P, Murray K F. et al . PegInterferon with or without Ribavirin for chronic hepatits C in children and adolescents: final results of the PEDS-C trial. Hepatology. 2008; 48 418A

Google Scholar
738 Figlerowicz M, Sluzewski W, Kowala-Piaskowska A. et al . Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C. Eur J Pediatr. 2004; 163 265-267

Google Scholar
739 Gonzalez-Peralta R P, Kelly D A, Haber B. et al . Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology. 2005; 42 1010-1018

Google Scholar
740 Kowala-Piaskowska A, Figlerowicz M, Mozer-Lisewska I. et al . Effects of treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. Przegl Epidemiol. 2005; 59 491-498

Google Scholar
741 Sluzewski W, Mozer-Lisewska I, Figlerowicz M. et al . Current trends and first clinical studies of therapy for chronic hepatitis C in children using pegylated interferon alpha and ribavirin. Przegl Epidemiol. 2005; 59 595-599

Google Scholar
742 Wozniakowska-Gesicka T, Kups J, Wisniewska-Ligier M. Sustained virological response in children with chronic hepatitis C treated with interferon alpha and ribavirin. Przegl Lek. 2005; 62 1405-1408

Google Scholar
743 Jara P, Hierro L, Vega de la A. et al . Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J. 2008; 27 142-148

Google Scholar
744 Gehring S, Kullmer U, Koeppelmann S. et al . Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha. World J Gastroenterol. 2006; 12 5787-5792

Google Scholar
745 Kowala-Piaskowska A, Mozer-Lisewska I, Figlerowicz M. et al . Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. Pharmacoepidemiol Drug Saf. 2007; 16 1095-1103

Google Scholar
746 Urganci N, Gulec S, Dogan S. et al . Interferon and ribavirin treatment results of patients with HBV-HCV co-infection cured of childhood malignancies. Int J Infect Dis. 2006; 10 453-457

Google Scholar
747 Polywka S, Pembrey L, Tovo P A. et al . Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J Med Virol. 2006; 78 305-310

Google Scholar
748 England K, Pembrey L, Tovo P A. et al . Excluding hepatitis C virus (HCV) infection by serology in young infants of HCV-infected mothers. Acta Paediatr. 2005; 94 444-450

Google Scholar
749 Bortolotti F, Verucchi G, Camma C. et al . Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology. 2008; 134 1900-1907

Google Scholar
750 Manns M P, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006; 55 1350-1359

Google Scholar
751 Conte D, Fraquelli M, Prati D. et al . Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology. 2000; 31 751-755

Google Scholar
752 Gervais A, Bacq Y, Bernuau J. et al . Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. J Hepatol. 2000; 32 293-299

Google Scholar
753 Gibb D M, Goodall R L, Dunn D T. et al . Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet. 2000; 356 904-907

Google Scholar
754 Okamoto M, Nagata I, Murakami J. et al . Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody. J Infect Dis. 2000; 182 1511-1514

Google Scholar
755 Polywka S, Feucht H, Zollner B. et al . Hepatitis C virus infection in pregnancy and the risk of mother-to-child transmission. Eur J Clin Microbiol Infect Dis. 1997; 16 121-124

Google Scholar
756 Marine-Barjoan E, Berrebi A, Giordanengo V. et al . HCV/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus?. AIDS. 2007; 21 1811-1815

Google Scholar
757 Hayashida A, Inaba N, Oshima K. et al . Re-evaluation of the true rate of hepatitis C virus mother-to-child transmission and its novel risk factors based on our two prospective studies. J Obstet Gynaecol Res. 2007; 33 417-422

Google Scholar
758 Mast E E, Hwang L Y, Seto D S. et al . Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005; 192 1880-1889

Google Scholar
759 Steininger C, Kundi M, Jatzko G. et al . Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J Infect Dis. 2003; 187 345-351

Google Scholar
760 Pappalardo B L. Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. Int J Epidemiol. 2003; 32 727-734

Google Scholar
761 Ohto H, Terazawa S, Sasaki N. et al . Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med. 1994; 330 744-750

Google Scholar
762 Ceci O, Margiotta M, Marello F. et al . Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr. 2001; 33 570-575

Google Scholar
763 Dal M olin G, D’Agaro P, Ansaldi F. et al . Mother-to-infant transmission of hepatitis C virus: rate of infection and assessment of viral load and IgM anti-HCV as risk factors. J Med Virol. 2002; 67 137-142

Google Scholar
764 EPHN, Network EPHCV . A significant sex- but not elective caesarean section-effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis. 2005; 192 1872-1879

Google Scholar
765 Tovo P A, Palomba E, Ferraris G. et al . Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV Infection in Children. Clin Infect Dis. 1997; 25 1121-1124

Google Scholar
766 Zanetti A R, Tanzi E, Romano L. et al . A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology. 1998; 41 208-212

Google Scholar
767 Boxall E, Baumann K, Price N. et al . Discordant outcome of perinatal transmission of hepatitis C in twin pregnancies. J Clin Virol. 2007; 38 91-95

Google Scholar
768 EPHN, Network EPHCV . Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. Br J Obstetr Gynaecol. 2001; 108 371-377

Google Scholar
769 Inui A, Fujisawa T, Sogo T. et al . Different outcomes of vertical transmission of hepatitis C virus in a twin pregnancy. J Gastroenterol Hepatol. 2002; 17 617-619

Google Scholar
770 Barlow K M, Mok J Y. Dizygotic twins discordant for HIV and hepatitis C virus. Arch Dis Child. 1993; 68 507

Google Scholar
771 Bhola K, McGuire W. Does avoidance of breast feeding reduce mother-to-infant transmission of hepatitis C virus infection?. Arch Dis Child. 2007; 92 365-366

Google Scholar
772 Polywka S, Feucht H, Laufs R. Die chronische Hepatitis C der Mutter ist keine Kontraindikation für das Stillen. Bundesgesundheitsbl. 2003; 46 739-743

Google Scholar
773 Resti M, Azzari C, Mannelli F. et al . Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ. 1998; 317 437-441

Google Scholar
774 Zanetti A R, Tanzi E, Paccagnini S. et al . Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet. 1995; 345 289-291

Google Scholar
775 EASL International Consensus Conference on hepatitis C. Paris, 26 – 27 February 1999. Consensus statement. J Hepatol. 1999; 31 (Suppl 1) 3-8

Google Scholar
776 Empfehlung des Bundesinstitutes für Risikobewertung. Ergänzung zu den Empfehlungen der Nationalen Stillkommission zu Hepatitis C und Stillen vom März 2001. Bundesgesundheitsbl. 2003; 46 790

Google Scholar

7 * Diese Autoren haben gleichberechtigt zu dieser Leitlinie beigetragen.

Dr. Matthias Dollinger Ph. D.

Klinik für Innere Medizin I, Martin-Luther-Universität Halle-Wittenberg

Ernst-Grube-Straße 40

06120 Halle/Saale

Phone: ++ 49/3 45/5 57 26 65

Fax: ++ 49/3 45/5 57 22 53

Email: matthias.dollinger@medizin.uni-halle.de

>